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Giardia lamblia is an enteric protozoan parasite, which causes infection in humans worldwide. 
The impact of the infection varies from asymptomatic carriers to severe disease such as 
malabsorption syndrome. Evidence for acquired immunity against Giardia infection has been 
found in previous studies. CD4+ T cell responses have been detected in humans, but data 
regarding cytokine producing profiles of these T cells is limited.  
  This study aimed to develop a flow cytometric method to investigate Giardia-specific 
CD4+ T cell responses in individuals with recent giardiasis. Early cytokine profiles in addition 
to later surface markers and proliferation were combined to explore Giardia-specific CD4+ T 
cell immune responses by flow cytometry.  
  In the development of the flow cytometric assay,  fluorochrome-conjugated antibodies 
were titrated and different clones tested, detector voltages on the flow cytometer were adjusted, 
CellTrace proliferation dye labeling method and concentration was optimized, spectral overlap 
was minimized, compensation matrices were acquired and different fixation and 
permeabilization reagents were tested.  
  To explore the function of the assay, cultures of peripheral blood mononuclear cells 
(PBMCs) from a group of individuals with recent giardiasis were stimulated with Giardia 
assemblage A and B sonicated soluble proteins (SSA and SSB), and responses were compared 
to responses in PBMCs from a group of low risk healthy controls. Early cytokine profiles in 
addition to later surface markers and proliferation were compared between these groups to 
explore Giardia-specific CD4+ T cell immune responses by flow cytometry. The first assay (day 
one assay) investigated cytokine expression of TNA-α, IFN-γ, IL-17A, IL-10 and IL-4 in 
effector memory CD4+ T cells (CD197-CD45RA-) after 24 hours of stimulation with Giardia 
soluble proteins and controls antigens. The other assay (day six assay) investigated proliferation 
by CellTrace dye dilution and activation markers HLA-DR, CD45RO, CD25 and CD26 after 
six days of stimulation.   
  The results were analyzed in FlowJo, and statistical analysis was done using SPSS. 
Cytokine responses were stronger in the Giardia exposed group when stimulated with SSA and 
SSB, but only IL-17A production was found to be significantly elevated in this group. Two 
participants with current, on-going, giardiasis had markedly elevated production of all 
cytokines, except IL-4, in response to SSA and SSB, but not to control antigens.  





significantly different between the groups when stimulated with SSA. A positive correlation 
between SSA and SSB induced effector memory CD4+ T cell cytokine production, as well as 
proliferation responses was found, indicating considerable cross-reaction between these two 
assemblages.  
  In conclusion, we find that the developed assay performed well and can be used to assess 
Giardia-specific immunity, but it has some shortcomings.  Although the assay showed 
generally higher responses in the giardiasis exposed group for most of the outcomes, only IL-
17A production, and HLADR+CD45RO+ activation turned out to be statistically significant. 
Future studies using purified recombinant Giardia proteins as antigens may improve this. Some 
of the low risk controls may also be cross-reacting or unknowingly been previously exposed to 
Giardia. A novel finding in this study is that Th17 CD4
+ T cells may play an important role in 
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1. Introduction  
1.1 Immune system of humans  
1.1.1 The innate and adaptive immune system of humans 
The immune system is an advanced interplay between many different cells in order to protect 
an individual against infective agents and harmful components [1]. These agents can for 
instance be invading microbes and other potential harmful microbe parts such as toxins (usually 
proteins and polysaccharides) or chemicals. A collective term for these agents is antigens. 
  Antigens are classified as non-self-molecules and are capable of triggering an immune 
response. Sometimes the immune system starts recognizing its own body components as 
antigens, and a state called autoimmunity can be initiated.  
  The immune system can be divided into a two-part system, where one is activated as an 
initial rapid response and gives warnings for the other, which requires longer time to get 
activated, but has a remarkable capacity of generating immunological memory. These two 
systems can accordingly be named the innate immune system and the adaptive one.   
Figure 1.1 displays the components and activation time of the innate and the adaptive immune 
responses. 
    
 
Figure 1.1: Components of the innate and adaptive immune systems and activation time.  
The innate immune system is activated within hours of intrusion.  The adaptive immune system takes longer time 






Cells in the immune system can express specific receptor/ligands on their cell surface known 
as cluster of differentiation (CD). CD expressed on the surface of a cell can be used to 
distinguish between different cell types, and may be used for phenotyping [1].  
 
1.1.1.1 The innate immune system 
The innate immune system is congenital and is the initial response against an infection. It is not 
specific against certain types of antigens, because it is present before an infection takes place. 
The antigens recognized by the innate immune system, are defined in the germ-line of humans, 
and is predetermined before a human encounters antigens in the environment after birth. The 
innate immune system will therefore react the same way against all potential antigens, and no 
memory responses will be generated [1].  
  Parts making up the innate immune system are: different barriers, where both physical 
and chemical, (including the skin, and mucosal surfaces), antimicrobial substrates produced by 
different cells, phagocytic cells and also a cell type called natural killer cell (NK cell). The 
phagocytic cells compromise of neutrophils, mast cells, macrophages and monocytes. Dendritic 
cells and macrophages, are called antigen-presenting cells (APC), and can bind and ingest 
intruding microbes and mitigate, reducing the antigen load in the host.  
  Proteins circulating in the blood are also a part of the innate immune system, where 
proteins of the complement system (C1-C9) and other inflammatory proteins are vital. The 
complement system comprises of serum and cell surface proteins, which can react with one 
another or cooperate with other immune components, in eradication of antigens. An activation 
of the complement system leads to a cascade of happenings, leading to a proteolytic cleavage 
of the protein C3, creating the products C3a and C3b [2]. This will again trigger cleavage of C5 
to C5a and C5b. C3a mediates inflammation, favoring phagocyte recruitment and the C5a work 
as a chemoattractant (entice phagocytes to migrate to the infection site). C3b coat surfaces of 
microbes and work opsonic (enhance phagocytosis). C3b can also bind with C6, C7, C8 and 
C9, making a membrane attack complex and lyse/penetrate antigenic cell membranes by 
making pores [2].  
   Other inflammatory proteins important for the innate immune system, are called C-
reactive protein, serum amyloid A protein, proteinase inhibitors and coagulation proteins [2]. 
 A type of highly specialized phagocytic cells are termed dendritic cells (DC). Dendritic 
cells (DC) possess important cellular elongations, called dendrites, and collect antigens 
constantly form i.e. lumens of mucosal surfaces. DCs can recognize pathogens by receptors for 





microbes expresses, such as double stranded RNA, carbohydrates such as lipopolysaccharides 
(LPS) and glycoproteins such as mannose-rich oligosaccharides [1].   
   After DC antigen uptake, DCs mature and can migrate to peripheral lymph nodes in 
order to start antigen specific immunity by interaction with lymphocytes of the adaptive 
immune system. The DC processes the sampled antigen into smaller peptide fragments and 
display them on a receptor called major histocompatibility complex (MCH). Two subclasses of 
MHC exist, and are termed class I, and class II. Class I MHC is found on every nucleated cell 
in the body and is recognized by CD8+ T cells. Class II MHC is displayed on APCs and is 
recognized by CD4+ T cells. This is described more in detail later. The display of antigen 
fragments on the DCs MHC class II receptor makes them into APCs. Through this receptor, 
DCs can present antigens to, and activate, cells of the adaptive immune system. They are 
therefore know as a bridge between the two immune systems [2].  
 
1.1.1.2 The adaptive immune system 
The adaptive immune system (or acquired immunity) on the other hand is stimulated by foreign 
substances and, when activated can confer specific protection against a specific infectious 
agent. It is established only after encountering foreign substance and needs longer time to be 
effective, compared to the innate and initial immune response. The adaptive immunity consists 
of different cells making up an advanced interaction. The main cells involved are the 
lymphocytes and the products they secrete against an infectious agent [1]. The adaptive immune 
system is capable of differentiating between very similar microbes and react towards them in 
different ways. Existence of memory cells makes an individual capable of eliciting a faster and 
stronger immune response towards previously encountered pathogens. Memory immune 
responses and antigen specificity are characteristics of the adaptive immune system. The 
specific memory responses can exists for several years after an antigen exposure, and give 
protective immunity [1].   
  The adaptive immune responses can be divided into two different pathways, where one 
is called humoral immunity, produced by B cells, and the other one is called cell-mediated 
immunity, and involves T cells.  
 
1.1.1.3 Humoral and cellular immunity 
Both humoral and cellular immunity is based on recognition of specific antigens or a part of it. 
The parts which they can recognize are called antigenic determinants or epitopes. An individual 





lymphocytes can distinguish between an enormous amount of antigens. When a lymphocyte 
finds its epitope and becomes activated, it can undergo clonal expansion (proliferation), where 
many clones of this lymphocyte can help in the removal of an antigen.  
  The cells responsible for the humoral immunity are called B lymphocytes, or B cells 
and most of these expresses the surface marker CD19. The maturation of B cells starts in the 
bone marrow, but before they are fully matured, they go into the circulation and thereafter travel 
to the peripheral lymphoid organs and here they can become fully matured. B cells have a 
membrane-bound antibody receptor which they use to recognize antigens. A differentiated B 
cell, called a plasma cell, produces proteins called antibodies or immunoglobulins (Ig) which 
are secreted into blood and on mucosal surfaces. The secreted antibodies’ major responsibilities 
are to recognize antigens and microbial secreted toxins, thereafter render them harmless and 
make them available for removal by several other cells or mechanisms (including the 
phagocytes and the complement system) [1].  
  Igs are highly specific proteins capable of distinguishing between different antigens. Igs 
can be separated into different classes called IgA, IgD, IgE, IgM and IgG. Polysaccharides and 
lipids stimulate naïve B cells into plasma cells producing Igs known as the IgM class, followed 
by a weak IgG response. This is recognized as a primary response. If the same infectious agents 
are met again, a secondary response can be triggered and is faster and stronger than the primary 
one. IgG is the dominant Ig in a secondary response [1].     
  The cellular immune responses are carried out by a cell type called T lymphocytes (T 
cells). T cells will mature completely in the thymus before they travel with the blood circulation 
and then reside in peripheral lymphoid tissues.T cells express a T cell receptor (TCR). A part 
of this receptor is called CD3 and can be used to identifythese cells. The TCR can be divided 
into αβ-TCR and γδ-TCR, where αβ-TCR is the most common one for T cells, and the γδ-TCR 
T cells usually lack CD4 and CD8 surface receptors (CD4 and CD8 are discussed later) and can 
mostly not recognize peptides displayed by the MHC on APCs [1]. The γδ-TCR T cells are 
mostly found in the intestine functioning as intraepithelial lymphocytes [4]. They make up 
around 3-5 % of T cells in peripheral blood [5].  
   T cells can only recognize epitopes having peptide structures and they have to be 
displayed on MHC expressed by APCs. Professional APCs include dendritic cells, 
macrophages and B cells, and they express MHC class II. Macrophages do not normally express 
MHC class II, but this receptor can be up-regulated during an immune response [1]. The most 
efficient APCs are the DCs, which can collect antigens entering the body by endocytosis, 





(CD45RA+/CD197+) by interaction of the MHC and the TCR. CD45RA is a high molecular 
weight surface receptor expressed on naïve T cells. This receptor will not react rapidly against 
recall antigens. During an activation, the expression of CD45RA will be lost, and the cell will 
instead express the low molecular weight structure, known as CD45RO. The CD45RO receptor 
reacts rapidly against recall antigens [1, 6].  
   A co-receptor (CD28) in addition to the TCR is needed for a naïve T cell to become 
activated. Activated T cells can thus turn into a memory cell, either a central memory cell 
(CD45RO+/CD197+) or an effector memory cell (CD45RO+/CD197-) [7]. The CD197 molecule 
is an important chemokine receptor for cytokines produced by lymphoid tissue and CD197 is 
known as a homing receptor. This receptor favors migration toward lymph nodes, where T cells 
can be activated into effector memory cells, provided they encounter the specific antigen for 
their receptor presented on MHC on an APC. The CD197 receptor will be lost during activation, 
and T cells will be able to migrate to the site of infection and produce cytokines as their effector 
function [1, 8].  
  Recently activated cells will express CD25 (an autocrine receptor for the cytokine IL-
2)[1]. Activated T cells can also be positive for a proteolytic enzyme, known as CD26, shown 
to be up-regulated during activation. CD26 can also be termed a recall antigen marker [9, 10]. 
HLA-DR is also a surface marker associated with activation occurring in later phases [10, 11]. 
Another activation marker for T cells is CD69, which is up-regulated in the early phases of 
activation [12].  
  The T cells can be divided into two major subsets where one is termed a helper T cell 
(Th cell), and another one is termed cytotoxic T cells (CD8
+). Some T cells are also functioning 
to inhibit or regulate immune responses and are termed regulatory T cell (Treg) [1].  
  Helper T cells (CD4+) recognize peptides in MHC class II displayed on DCs and become 
activated. After activation CD4+ T cells are responsible for secreting proteins called cytokines. 
Cytokines are messenger molecules that can exhibit different functions and can stimulate the T 
cell themselves to undergo proliferation, differentiation and stimulates surrounding cells. 
  Th cells can activate B cells into producing antibodies belonging to IgG, IgA or IgE 
class. The antibodies produced by plasma cells with help have better affinities for the respective 
antigens. Th therefore needed to initiate good B cell responses towards protein antigens. To 
induce B cell activation mediated by T cells, an already activated T cell have to recognize 
peptides displayed by the B cell’s MCH class II.  
  IgG is important for eradication of an antigen as macrophages express a receptor for this 





  A cytokine called interleukin-2 (IL-2) is produced by T cells and acts as a growth factor 
for the T cell itself and for nearby cells. T cells can also activate other cells such as macrophages 
(in conjunction with a cytokine called Interferon-γ) and other leukocytes [1].  
   Cytotoxic T cells express CD8, a membrane receptor recognizing class I MHC 
molecules found on all types of cells. These T cells become activated when a cell is displaying 
peptides on its MHC class I. Cytotoxic T cells monitor and may kill any host cells infected with 
virus or bacteria (making them go into apoptosis). The CD8+ cell mediated killing is crucial, as 
antibodies cannot reach the inside of infected cells.  
  A CD8+ mediated apoptosis is dependent on cytotoxic granules inside the cell. These 
granules contain perforin and express a surface marker known as CD107a. Theses granules will 
degranulate when CD8+ cells exert their function. CD107a will then be expressed on the surface 
of the cell and can be used as a marker of cytotoxicity. Perforin can also be used as a marker of 
cytotoxicity as this protein gets exposed during the triggered apoptosis of an infected cell, where 
it creates pores [8, 13].  
  The lymphocytes and their function of immune responses are displayed in Figure 1.2. 
 
Figure 1.2 Antigen recognition and effector functions of B cells and different subsets of T cells.   






1.1.1.4 Polarization of naïve CD4+ T cells 
Naïve CD4+ T cells can differentiate into different subsets, depending on the type of microbe, 
tissue and signaling molecules in their environment [14, 15]. The subsets of which naïve CD4+ 
T helper cells (Th) can polarize into include Th1, Th2, Th9 and Th17. Naïve CD4
+ T cells can 
also differentiate into a regulatory cell known as Treg [1]. The cytokines important for 
differentiation of a naïve CD4+ T cell, and the main cytokines the differentiated effector cell 
produce are displayed in Figure 1.3.  
  The Th1 subsets mainly produce pro-inflammatory cytokine crucial for the eradication 
of microbes residing inside cells. The cytokines most specific for this subset of helper cell are 
IFN-γ, TNF-α and IL-2. IFN-γ and TNF-α are important for cellular immunity, especially 
towards intracellular microbes. These cytokines also stimulate phagocytes during an infection, 
improving their phagocytic properties [1, 4, 16, 17].  
  The Th2 subset works antagonistically to the Th1 subsets, and can stop or regulate 
responses mediated by Th1. This subset is important for immunity against helminthic parasites 
and allergens. Typical cytokines produced by Th2 cells include IL-4, IL-5, IL-13 and triggers 
IgE production from B cells. A regulatory cytokine known as IL-10 is also a characteristic Th2 
cytokine [1, 16, 17].   
  The Th9 subsets can be associated with Th2 subset, as IL-4 is required for Th9 
development. The polarization of Th9 subsets are thought to occur both for naïve CD4
+ T cells, 
and for already polarized Th subsets (Figure 1.3). The characteristic cytokine for Th9 is IL-9 
[14].  
  The Th17 subset has IL-17 as their classical cytokine. This subset of Th cannot occur if 
INF-γ or IL-4 is produced [1]. Important properties for Th17 cells are to mediate pro-
inflammatory responses against extracellular microbes has been shown to cause tissue damage 
connected to autoimmune diseases [1, 4].  
  Tregs are essential for inhibiting or limiting immune responses and interleukin-10 (IL-
10) is a regulatory cytokine produced by these cells [1].  
  
1.1.1.5 Important cytokines relevant for polarization 
The messenger molecules, cytokines, can show pleiotropism and redundancy. Pleiotropism 
means that one cytokine can function on different kinds of cells, giving one cytokine the chance 
of carrying out different biological effects. Redundancy means that different cytokines can exert 
the same biological function and hence give the same responses. Combinations of cytokines 





an activation of another [1].  
  Some of the cytokines are important in mediating pro-inflammatory, anti-inflammatory 
or regulative reactions. Many of these cytokines are produced by CD4+ T cells and play vital 
roles in immune responses [1, 16].  
  Tumor Necrosis Factor alpha (TNF-α) is the main cytokine for acute inflammation and 
can cause systemic symptoms associated with infections. This cytokine can be termed pro-
inflammatory as it is an important cytokine in recruitment of various phagocytotic cells such as 
neutrophils and monocytes to site of infection, and for activation these. TNF-α also makes 
endothelial surfaces permeable to phagocytes by inducing  the endothelium to express adhesion 
molecules that facilitate phagocytotic migration to the site of infection [1].  
  Interferon-γ, IFN-γ, is the major cytokine for macrophage activation and is important 
for cellular immunity against  intracellular microbes. IFN-γ activates macrophages, influence 
differentiation of naïve CD4+ T cells to Th1 and promotes Ig switching in B cells. It is a pro-
inflammatory cytokine, and is a mediator in turning naïve CD4+ Th into a Th1 response and 
turning antibodies secreted by plasma cells into IgG type [1].  
  Interleukin-4, IL-4, is the main promoter for IgE antibodies secreted by plasma cells, 
and also an important mediator for the polarization of naïve CD4+ Th into a Th2. The Th2 
response is essential for mast cell/eosinophil-mediated reactions. IL-4 can be classified as a Th2 
characteristic cytokine [1].  
  Interleukin-17A, IL-17A, is a pro-inflammatory cytokine important for protection 
against bacterial infections. IL-17A is produced by a subtype of Th cells called Th17. The Th17 
cells require Transforming Growth Factor-β (TGF-β), IL-23 and innate cytokines such as IL-6 
in order to develop. IL-17A has a speculative role for being a promoter of destructive properties 
of autoimmune diseases in mice and also in inflammatory bowel disease in humans [1].   
  Interleukin-10, IL-10, is an important cytokine for inhibition of cell-mediated immunity. 
Due to the regulative properties of immune responses, it is characterized as a regulatory 
cytokine. It is likewise an inhibitor of macrophages. IL-10 is also known to inhibit INF-γ 


















1.2 Immunity in the intestine and the epithelial barrier  
Many organs are covered by mucosal surfaces including the gastrointestinal system, the 
respiratory tract, the reproductive and the urinary tract. These surfaces play an important role 
in protection against the environment [18].  
  The epithelium covering the small intestine is important for nutritional and hydration 
status in humans, as it absorbs both nutrients and is a regulator for water and electrolytes. To 
maximize the absorption capacity, enterocytes with microvilli make up an apical brush border 
with a huge surface area (size of a tennis court). Intracellular junctions and tight junctions 
between the epithelial cells are important for a working barrier function [18]. These junctions 
are made up of different proteins, including cytoskeletal F-actin and α-actin [19]. 
  Several different microorganisms flourish in the small intestine and make up a micro 
flora largely favorable for the human host. Other factors important for absorption, digestion and 
health include gastric acid, digestive enzymes, bile salts and peristalsis (involuntary constriction 
and relaxation of the muscles) and CD8+ intraepithelial T lymphocytes [18].  
  The barrier covering the small intestine is renewed as often as every 4-5 days by 
undifferentiated, proliferating progenitor cells in the crypts, while the villi are replaced with 
non-proliferating cells, which are not specialized. Stem cells at the base of the crypts is the 
source of three cells types that reside in the villus. These cells are called absorptive enterocytes, 
enteroendocrine cells and goblet cells. The stem cells can also differentiate into a cell located 
at the base of the crypts that is called Paneth cells [18]. A demonstration of the renewal of some 
of these cells can be seen in Figure 1.4.  
  
Figure 1.3: Differentiation of naïve CD4+ 
T cells and their signature cytokines. 






Figure 1.4: Renewing of the cells covering the epithelial barrier in the small intestine.  
The renewal of villus, paneth cells and epithelium originated form the crypts of the small intestine. The figure is 
adapted from [20].  
 
1.2.1 Secretory substrates protecting the small intestine  
Goblet cells are responsible for production of mucin glycoproteins, making up a protective inner 
and outer mucus layer. Paneth cells produce α-defensins which are peptides with antimicrobial 
properties [18]. The epithelium secretes lactoferrin, lysozyme, peroxidase, Nitric oxide [21], 
reactive oxygen species (ROS) [19], cathelicidin and α- and β-defensins [18].   
  Nitric oxide (NO) is produced enzymatically by NO synthase (NOS) and requires the 
protein arginine. The NO has antimicrobial properties and can act towards both bacteria and 
parasites [22]. Many pathogens infecting the intestine absorb and utilize free arginine from the 
surrounding milieu in hosts. Several different pathogens been suggested to compete for free 
arginine including Mycobacterium, Giardia, Trypanosoma, Helicobacter, Schistosoma and 
several Salmonella types. This strive for free arginine makes it a competition between the host 
cells and the pathogens [3, 23, 24].   
  Right underneath the epithelial barrier, a region called lamina propria is found. Cells 
mediating immune responses can also be found here and include lymphocytes, macrophages, 





cells are a cell type important for the immunity against helminthic infection and also for part of 
allergic reactions, producing histamine [25].   
  Antibodies have a specific way of getting into the intestinal lumen in order for them to 
perform their functions against pathogens. The polymeric Ig receptor is needed in the transport 
of IgA and IgM from the lamina propria to the lumen. IgA is the dominant Ig on mucosal 
surfaces. Transport of IgG happens via the neonatal Fc receptor, and can go both directions 
(from lumen to lamina propria and vice versa). IgE is often made in response to parasitic 
infections and can be transported via CD23(FCεRll) [18].  
 
1.2.2 Recognition of pathogens in the small intestine 
Pathogens residing in the intestinal lumen need to be recognized by host cells in order to elicit 
a defense mechanism in the form of adaptive immune responses. There are many ways for this 
immune response to happen, but three pathways are of special importance. One of the pathways 
involve M cells (specialized epithelial cells), lymphoepithelial structures found in Peyer’s 
patches(a region in the intestine resembling lymphoid tissue) in addition to isolated lymphoid 
follicles. The M cells can take up antigens from the lumen of the small intestine and forward 
them to APCs, without being one themselves. Another pathway important for stimulating 
immune responses is mediated by transcytosis (transportion of macromolecules from the 
surroundings and into the interior of a cell), where Ig bound to antigens make up complexes 
which can be presented to and captured by professional APCs (dendritic cells) found in lamina 
propria. After activation, these APCs can migrate to other lymphoid structures in the body, 
interact with lymphocytes and thus activate a systemic adaptive immune response. The last 
pathway is where dendritic cells can be located in the submucosa in close proximity to the 
epithelium. Dendritic cells can extend their dendrites between epithelial cells in order to collect 











1.3 The gut infective parasite Giardia lamblia  
 
1.3.1 A brief historical perspective of the gut parasite Giardia lamblia 
Giardia lamblia (synonyms: Giardia duodenalis, Giardia intestinalis) is a gastrointestinal 
protozoan parasite known to infect different hosts, including humans [26]. It was the first 
protozoan parasite, infectious to humans, to be discovered by the Dutchman Antonie van 
Leeuwenhoek in 1681 [27]. Vilem Lambl redescribed Giardia later, in 1859, and published 
self-made drawings of the protozoan [28].  
  The parasite was isolated and described in human fecal samples, but still physicians 
disagreed about whether or not the parasite was a pathogen or a commensal, i.e. an innocent 
organism benefiting from host interaction with humans. Research and clinical reports from 
1915 and onwards showed, however, that Giardia was associated with diarrheal disease and 
therefor a pathogen [28].  
  Although the timespan since discovery has been long, the epidemiology and 
nomenclature of this organism can still be considered confusing and the pathology different 
than was earlier described. Transmission due to contaminated drinking water and infection with 
this protozoan, causing the disease known as giardiasis, was first proved when well-documented 
reports came out in the 1960s in the United States of America [27, 28].  Today the leading route 
of transmission is the fecal-oral route either indirectly through water or food or directly between 
persons [27, 29].  
  Giardia lamblia (from now on Giardia) can be termed an antediluvian diverging 
organism [30]. Figure 1.5 graphically shows the evolution of the eukaryotes, and places Giardia 
to the earliest branches of an rRNA-rooted tree, together with other organisms, all termed 
Archezoa.  
  Some people have disagreed about whether Giardia developed before or after the 
mitochondrial acquisition, and it has been proposed that Giardia has had mitochondria, but has 








Figure 1.5: A schematic overview of the evolution of eukaryotes, shown by a rooted rRNA-tree.   
The branches representing the diplomonands, parabasalids and the microsporidia have a shared root, showing that 
they branched off before mitochondrial acquisition. The lineages that can be found further to the right of the root 
are thought to be newer branches, consisting of uni- and multicellular organisms, called the ‘Crown’ groups [32]. 
This figure is borrowed from [33]. 
 
1.3.2 Taxonomy, nomenclature and genotypes of Giardia 
Giardia belongs to the phylum Sarcomastigophora, and to the class Zoomastigophora. The 
protozoa is classified as a member of the order diplomonandia, and is part of the binuceated 
(two nuclei inside its cell) flagellates group, known to populate anaerobic or microaerophilic 
habitats. At the present time, Giardia is part of the supergroup Excavata [26, 34].   
  Giardia cells offer exceptional opportunities for expanding the insight into essential 
cellular pathways characterized by eukaryotic cells, and for discovering new molecular 
mechanisms. Giardia has a metabolism resembling bacteria, and shows compliant growth in 
cultures, making it a good ‘prototype’ in order to examine relic organelles, cellular 
differentiation and other cellular mechanisms [34].   
  Eight different genotypes of Giardia lamblia have been classified, known as 
assemblages A-H, and can infect mammals [23, 26]. Assemblage A and B are infective to 





morphological appearance identified with light microscope. For instance Giardia agilis infects 
amphibians and  Giardia muris infects rodents, birds and also reptiles [26].   
1.3.3 Epidemiology of giardiasis 
Several waterborne pathogens, found in industrialized and in developing countries, cause 
diarrheal diseases. Annually, there is an estimated 4 billion cases of diarrheal disease worldwide 
and these result in approximately 2,2 million deaths [35]. Out of the diarrheal diseases, Giardia 
has been estimated to give up to 280 million symptomatic human infections annually. World’s 
health organization (WHO) classified giardiasis as a neglected disease in 2004 [34, 36].   
  Giardia is a parasite often identified in waterborne outbreaks and is found throughout 
the world [37]. Prevalence rates of infection in the industrialized world is estimated to be 5 % 
(3-7 %), and 20 % (4-43 %) in third world countries [19]. Giardiasis is frequently recognized 
as acute, but can turn into a chronic disease lasting for months or years, both with or without 
symptoms [38].    
  Giardia together with Cryptosporidium are the two main waterborne infections caused 
by protozoan parasites producing diarrhea in humans worldwide. These infections can be 
transmitted by fecal-oral route, water/swimming pools can be contaminated with parasites 
originating from animals or humans. Infection between family members have been documented 
and infection can occur during sexual relations involving oro-anal contact [28, 39].  
  A large outbreak was seen in Bergen, Hordaland County in 2004. A Giardia outbreak 
in this proportion had never been registered in this non-endemic country before. 1300 persons 
had laboratory confirmed positive Giardia stool samples and 2500 people underwent medical 
treatment due to this outbreak [40].   
  People infected with Giardia in industrialized countries, usually have acquired the 
disease through travelling in tropical or developing countries where Giardia is endemic. Figure 
1.6 displays returning German travelers, where those returning from India and West-Africa had 
higher risk of  returning with Giardia infection [41].   
  Giardia outbreaks are common in the USA. A surveillance of Giardia positive cases 
from 2006-2008, demonstrated in Figure 1.7 shows age distribution and numbers of cases. 
Young children between 1-4 years are most prone to infection, both in the USA and worldwide 









Figure 1.6: Giardia infection rates of returning German travelers.  
Giardia positive cases among German travelers. The risk of infection per 106 cases is highest in the countries India 
and West-Africa. Figure borrowed from [41].  
 
 
Figure 1.7 Demographics of Giardia infection in the United States of America from 2006-2008.  







1.3.4 Clinical manifestations  
Giardia infection in humans can on one hand give acute or chronic diarrhea, and at times result 
in more serious complications such as malabsorption syndrome. On the other hand it can also 
be an asymptomatic infection where the individual is unaware of the parasite [28]. Even if the 
infection can be self-limiting or be treated with medicines, it can influence the quality of life to 
a certain extent [3, 29]. The infectious dose is small, only 10 cysts are needed to establish the 
infection [34].  
  Clinical manifestations usually occur after 6-15 days of incubation. When the infection 
is symptomatic, it can cause watery diarrhea, epigastric pain, nausea and vomiting, which may 
results in weight loss [3, 29]. The diarrhea caused by Giardia can give rise to a severe disease, 
termed malabsorption syndrome [3].  In some intestinal biopsies from chronically infected 
individuals, atrophy of the villi has been found by microscopic analysis. Malfunction of the 
Na+-glucose uptake and microvillus brush border disruption have additionally been seen [43]. 
A correlation between symptomatic disease and a dysfunction of the epithelial barrier in the 
intestine has been suggested [3].   
  The impact of the infection is often more severe in young children, in malnourished 
persons, and in individuals incapable of developing an immune response following exposure to 
Giardia. The complications of infection can be macronutrient and micronutrient shortages. 
Vulnerable children susceptible to infection can due to these nutrient deficiencies suffer failure 
to thrive resulting in retarded growth and development [28, 29].   
  Normally, it takes between a few days and up to approximately 6 weeks to eradicate a 
Giardia infection spontaneously without medication [38, 44]. However, giardiasis can be 
treated with antibiotics of the 5-nitromidazole compounds, metronidazole commonly being the 
first choice [34, 45]. The different manifestations seen, can be due to different factors, such as 
Giardia genotype, the virulence of the Giardia strain, the antigenic variation, how large the 
ingested dose of cysts was, previous Giardia infection, age of the individual, other ongoing 
infections and the clinical state of the hosts immune system [19, 46-48]. A study with gerbils 
(an animal that can be infected with both the Giardia assemblages infective to humans) showed 
different durations of infections and probability of re-infection, when alternating re-infection 
with Giardia assemblage A or B. The gerbils previously infected with assemblage A showed 
resistance to be infected with both of the assemblages, while gerbils previously infected with 





responses are induced by the two assemblages, and cross-reactivity exists [47].   
 
1.3.5 Diagnosis  
Microscopic analysis looking for cysts in stools samples of infected individuals can be used to 
determine Giardia infection in individuals. Giardia cysts can be excreted only sporadically, 
and therefore examination of several stool samples will give better sensitivity. Three separate 
stool samples collected on different days will increase chances of getting a positive test and 
thus increase sensitivity to around 90 % [37].    
  Analysis for presence of Giardia can also be done by polymerase chain reaction (PCR). 
The PCR aims to detect the 18S gene found in Giardia, and has shown to have higher specificity 
and sensitivity than other diagnostic methods [49].  
  Analysis of trophozoites in duodenal contents can also be used to diagnose Giardia, but 
is a more invasive method and associated with more discomfort for the patient, than for stool 
sample examination [26].  
 
1.3.6 Treatment of giardiasis  
Giardia infections are usually treated with metronidazole as a common first line choice [45]. 
Metronidazole is the only licensed drug that can be used against giardiasis in Norway. 
This antibiotic has shown to result in successful eradication of the parasite in 60-90 % of the 
cases. Several antibiotics may be used to treat Giardia, if there are unsatisfactory responses to 
metronidazole. They are here listed according to empirical preference and range of efficacy 
effectiveness: Tinidazole (74-100 %), quinacrine (92-100 %), albendazole (24-100 %) and 
furazolidone (80-100 %). Pregnant women should however use paromycin (55-90 %) [45]. 
  It has been proposed in Norway to use combination therapy, if the first-line antibiotic, 
metronidazole fails. A second line choice consists of albendazole in combination with 
metronidazole. Paromomycin can be a third line choice and an option in pregnancy. Quinacrine 
in combination with metronidazole can be a fourth line choice [45].  
 
1.3.7 Giardia Biology  
The trophozoite has a shape, which bulges outwards on the back and bulges inwards in the 
front, where the adhesive disc (a cytoskeletal organelle [19]) is found. The length of a 
trophozoite is usually 10-12 µM and is about 5-7 µM wide. One or two structures can be found 





hammers. Giardia also have 8 motility organs known as flagella, which consists of four pairs 
[26]. Giardia has been recognized to be deficient of mitochondria [33] and also lacking a 
normal endoplasmatic reticulum and a Golgi apparatus [30].   
   Two identical nuclei containing nucleolus are found in the upper part of the trophozoite 
and can thus look like two eyes. Central- and peripheral mitosomes and peripheral vesicles are 
organelles found within Giardia. Overview of the parasite’s two stages, the trophozoite and the 
cyst, can be seen in Figure 1.8. The ventral adhesive disc, used for attachment, and the flagella 
are consisting of a type of Giardia-specific cytoskeleton proteins termed the giardin family, 
unique for this parasite, and the tubulin family [26, 34].   
    
 
Figure 1.8: The trophozoite state of Giardia (left) and the cyst state of Giardia (right).  
The flagella AF,CF, VF and PLF, seen on the trophozoite are abbreviations for anterior, caudal, posterior-lateral 
and ventral flagella. Picture borrowed from[34] and colors modified.  
 
The cysts measures 7-10 µM in length and has an oval shape. The cyst wall measures 0.3 µM 
[26, 28]. When Giardia is a cyst, the adhesive disc and the flagella are broken into pieces 
(axonemes) during encystation and stored as fragments inside of the cyst [19]. The cyst has four 
nuclei inside the cell.  
 
1.3.7.1 Cell cycle of Giardia  
Giardia’s natural habitat is in the gastro-intestinal tract system, preferably in the small intestine, 
where it can adhere to the host’s intestinal mucosa in the duodenum and jejunum [19]. The 
parasite has however been found at more distal sites of the intestine [22].  





and a quadrinucleated cyst stage. The cyst can be termed a non-replicating infectious form and 
the trophozoite a symptom causing and replicating vegetative form. The cyst can live for many 
months outside its host, provided that the conditions are cool and moist [26, 34, 48]. 
  The giardial life cycle can be divided into four different steps, where the first one is 
excystation(I), followed by adherence to brush border villi in the intestinal epitelium (II), 
trophozoite replication (III) and encystation in order to infect other hosts (IV) [28]. 
 When a cyst has been ingested, it can excyst in the upper part of the small intestine, 
forming two trophozoites. These disease-causing trophozoites further replicates by binary 




   
 
  The conversion of a cyst to a trophozoite, excystation, making an excyzoite, is catalyzed 
by acidic pH (1.3-4 [26]) in the host stomach. Further on the cyst completes its differentiation 
in the duodenum where the pH is 6.8-7.0. The excystation is finished when the cyst is exposed 
to excretions from the pancreas. Proliferation/cytokinesis of the trophozoites can at this point 
(30 minutes after cyst wall disruption [26]) start and the infection is established.   
  The conversion the other way, encystation, happens in the small and large intestine when 
the surrounding milieu have low concentrations of cholesterol or high concentrations of bile 
acid and a basic pH [34, 50]. The infective cysts can then be parted from the host mixed in feces 
and infect other hosts by the fecal-oral route [51].   
  
Figure 1.9: The replication process of 
Giardia lamblia The cyst, or the non-
replicating infective state, is the first and 
last step in an infection with Giardia. The 
excyzoite is an intermediate before the 
vegetative, disease causing and replicating 
cysts are formed. The trophozoite has to 
undergo encystation before becoming a 
cyst again and can infect other hosts. 





1.3.8 Host-parasite interaction  
Trophozoites of Giardia have been identified to reside in close proximity to the top of 
enterocytes in the intestine, and also in the small intestinal crypts, where they can attach to the 
surface of the host cells. Giardia can only attach to the host cells, but is not invasive [23, 28]. 
Figure 1.10 demonstrates a Giardia  trophozoite attached to human epithelium in the small 
intestine.  
  Several in vitro experiments have shown that Giardia could rearrange some of the 
proteins binding the enterocytes together with tight junctions. Proteins found to be disrupted in 
vitro are the epithelial cell F-actins and α-actins, impairing the epithelial barrier function [19]. 
An experiment using a mouse model also showed a cytoskeletal remodeling of the epithelial 
barrier in the small intestine [52].  
 
 
Figure 1.10: Attachment of a Giardia trophozoite of the microvillus border on the top of epithelial cells of 
the human intestine.  
Photo borrowed from [26] 
 
 Replicating trophozoites have incomplete capacity to biosynthesize fat derived products 
such as membrane lipids, cholesterol and fatty acids. Accordingly, Giardia needs to depend on 
supplies from the surroundings. Lipids and fatty acids consumed from the host surroundings 
can be utilized as an energy source and biogenesis of different organelles. Fatty acids and 
cholesterol have both shown evidence of being important in the involvement and regulation of 
encystation and cyst differentiation [50].  
  Giardia use a pathway named the arginine dehydrolase (ADH) pathway to obtain 
energy. In this pathway arginine deiminase (ADI) has shown to start a progress of an 
irreversible catabolism, where free arginine from the host is converted to citrulline and NH4
+ in 





  The consumption of arginine, has been proposed to affect enterocytes in the intestine by 
reducing proliferation of stem cells in crypts. In this manner, it can impair homeostasis of the 
intestinal epithelium and thereby induce villi shortening leading to increased permeability in 
the intestine and cause diarrhea [23] 
1.3.9 Antigenic variation and virulence factors  
Giardia is not found to produce any toxins, and the knowledge regarding the main 
characteristics for defining parasite-host interactions, responsible for causing different outcome 
for disease is limited [22].    
  The adhesive disc and flagella are important for the parasite to avoid removal by 
peristalsis from the host’s intestine. The adhesive disc provides the parasite with suction 
properties, and enables attachment to the epithelial barrier in the intestine of the host. The 
flagella on the other hand makes Giardia capable of moving or “swimming”, both in order to 
get attached to the host cells and to evade  peristaltic movements by the intestines [34].  
  The trophozoite form of Giardia is able to switch major surface molecules, making the 
parasite capable of evading the immune system in the host. The surface molecules are called 
variant-specific surface protein (VSP), and only one out of around 250 VSP genes are expressed 
on the surface at any time point. VSPs are bound to the membrane and have an extracellular N-
terminal which is variable and a C-terminal which is more conserved [51].  
  ADI is recognized as a metabolic enzyme, but earlier findings shows that ADI has a 
capability of citrullinate the VSPs on the surface of Giardia cells. This modifies the original 
VSP biology and will alter the cytotoxic antibody responses from the host [51]. It has been 
suggested that Giardia-mediated VSP shifting is driven by host antibodies, and thus making 
the parasite evade the immune system of the host [53].  
  Cysteine proteases have been found in Giardia and these have been thought to be a 
virulence factor as they have shown to be capable of cleaving IgA from the host [26]. 
  The enzyme ADI converts arginine into citrulline as stated above. Earlier findings 
suggest that ADI is used as a competitor for the free arginine to NOS in the host [51]. The 
competition can therefore be seen as a virulence factor as it disturbs host nitric oxide synthases 
from functioning normally, and thereby decrease the secretion of anti-microbial NO [3, 46]








Table 1.1: Overview of Giardia virulence factors. The table is adapted from [34].  
Virulence factors Role of the virulence factors 
Ventral adhesive disc Facilitate interaction between parasite and the 
intestinal endothelium 
VSPs on the cell surface Surface shifting of proteins in order to escape 
host Immunoglobulins 
Flagellar motility Evading elements in the intestinal lumen and 
avoid peristaltic movements of the intestine. 
Excretion of Arginine Deiminase Down regulation of host mediated production of 
Nitric oxide in response to infection, and 
citurullination of VSPs. 
Giardias differentiation from trophozoite to a 
cyst 
A mechanism to protect the parasite from exterior 
environment and to be able to infect other hosts. 
High cysteine protease Cleaves IgA in order to escape immune responses 
from host 
 
1.3.10 Cellular and humoral immunity against Giardia  
Eradication of, and protection against, Giardia is likely to be dependent on both B cell mediated 
antibody production and T cell mediated immune responses in the host-pathogen interaction 
[19, 54]. Different barriers and immunity against Giardia can be seen in Figure 1.11. 
 Aquired immunity has been shown to occur as mice challenged with a second Giardia 
infection had far less cysts in feces (98 % less) compared to an initial infection [55].  
  Individuals who earlier encountered Giardia  previously are less prone to infection, have 
been seen in humans who live in endemic areas. The infective rates of giardiasis have been 
lower than expected for people encountering the parasite often. This indicates that some sort of 
acquired immunity exists [42, 56]. Giardia-specific T cell memory  immune responses have 
been evaluated using flow cytometry and thymidine proliferation assay. A small but pristing 
CD4+ T cell responses was found to be present even 5 years after individuals were infected 
with, and successfully treated for Giardia, in the Bergen Giardia outbreak [10].    
  Likewise, a waterborne Giardia outbreak in 1985 in Creston, Canada showed that 





happened again in a five year period. Residents living in this area showed to have higher IgA 
and IgG specific antibodies towards Giardia compared to controls [57].  
  Most of our knowledge regarding both the cellular and humoral immune responses 
against Giardia is based on studies in mice. CD4+ T cells have been shown to be necessary for 
immediate responses. Mice without CD4+ T cells cannot control a Giardia infection. B cell 
mediated antibody production did not show to be needed the same way as CD4+ T cells for the 
regulation of an acute Giardia infection [58].  Chronic infection can be caused by decreased or 
nonexistent CD4 T cells, and gives evidence that these cells are crucial for the murine defense 
against Giardia [58, 59].  
  An earlier study found that IFN-γ was secreted by human intestinal and blood CD4+ T 
cells when stimulated with Giardia trophozoites. The CD4+ T cells were also found to be 
proliferating in response to the Giardia parasites, suggesting specific proliferation of antigen-
specific CD4+ T cells [60].  
  T cells expressing αβ-TCR has been recognized to be of crucial importance in order to 
control an infection in mice, whereas T cells expressing γδ-TCR have not shown importance 
[58]. .  
Figure 1.11 Giardia infection and immune responses of the host over time.  
The timespan of giardiasis varies, but the incubation period is around one week. Natural barriers and the innate 
immune responses in the intestine are initial protection mechanisms against infection. Adaptive immune responses 
takes longer time to be established and is more specific. The figure is borrowed from [19]. 
   CD8+ T cells have not shown importance for the immunological control of murine 





increased number of cells in the crypts and villus. Diffuse villus shortening is a result of the 
injury and makes the intestinal surface area for absorption of micro-and macronutrients smaller, 
and can thus lead to malabsorption and diarrhea [43].  
  Studies in mice shown that neither Th1 nor Th2 responses are not required for protection 
against an acute infection of Giardia [58]. This finding opens up the possibility that other Th 
polarization could be important.  
  Giardia infections in cattle do often become of chronic character, and they can have 
cysts in their stools up to at least 112 days after being infected. It has been suggested that the 
adaptive immune responses in calves are not fully developed, giving fertile conditions for re-
infections frequently [53].  In vitro stimulation of PBMCs from calves with live Giardia 
trophozoites has shown increased transcription of IL-17 and FoxP3 mRNA in proliferating 
CD4+ T cells. This could mean that Treg and/or Th17 responses are important. CD4
+ αβ-T cells 
were shown to be proliferating in response to Giardia, supporting other findings that CD4+ T 
cells play a key role in the protective immunity against Giardia infection [53].  
 Antibodies are shown to inhibit trophozoite growth, and to kill the ones they recognize. 
Antibodies secreted by plasma cells are probably directed towards VSPs on the surface of 
Giardia. The antibodies can trigger shifting of the VSPs, and make Giardia capable of evading 
the immune system. Trophozoites which express other VSPs than the antibodies can recognize, 
will evade this immune response and continue their replication in the host [51].  
  IgA-deficient individuals have shown not be remarkably more prone to infection than 
healthy individuals are [22]. However, individuals with common variable immunodeficiency 
experience chronic Giardia infection more often and cannot control the infection efficiently. 
[46, 58]. Deficiencies in B cell mediated production of antibodies when CD4+ T cells are also 
not working normally is a probable reason for this [58].   
1.4 Flow cytometry and principles  
 
1.4.1 Flow cytometery - an introduction to principles and functions  
Flow cytometry is a remarkable method for phenotyping and characterize cells [61]. Flow 
cytometers are multiparametric instruments, as they can record multiple information each cell 
is carrying simultaneously. By using flow cytometry a homogenous and small population can 
be filtered out from a larger heterogeneous population.  
  Using flow cytometry for cell analysis is based on the light-scattering properties (also 
known as fluorescence emission) that cells exhibit.  Cytometry uses basic laws of physics such 





stained with a fluorescent antibody/dye, gives the opportunity for flow cytometry to distinguish 
between different cell types. Figure 1.12 shows how a sample is analyzed in a flow cytometer. 
  When the flow cytomtric laser has sent its beam on the cells, light will be scattered 
around. Light scattered in low angles (0.5-10 °) gives information regarding cell size and it is 
termed forward-scattered light (FSC). Whereas light scattered in large angles (90 °) gives 
information regarding cell granularity and is termed side-scattered light (SSC).  
 
 
Figure 1.13: Compartments of a flow cytometer.   
The analysis works by injecting a sample with cells into its system by using sheat fluid. The cells will be under 
pressure as they go into the system. A laser (many different can exist giving possibility of using different 
wavelengths) will send a beam out on the cells and they can become excited it carrying a stain or antibody. The 
light scattering from the cells will thereafter be picked up by a detector and a photomultiplier tube can convert 
signals and send it to a computer. Here the signals can be transformed to digital data. The signal can then be 
displayed on a computer screen. Figure is borrowed from [61]. 
1.4.1.1 Excitation and emission 
Fluorescence means that that a substance absorbs light of a wavelength/color and thereby emit 
the absorbed light in a different wavelength/color. The wavelength for which the substance 
emits is generally higher. Some components of cells (pyridine- and flavin-containing 
nucleotides in addition to porphyrins) exhibit autofluoroscence, which mean that they emit 
absorbed light at a higher wavelength without being stained [61].  





Some energy will also be lost to the surroundings as heat. A small Stoke’s shift will mean that 
the difference between absorption wavelength and emitted wavelength is little, giving small 
difference between the wavelengths. A large Stoke’s shift will on the other hand mean the 
opposite [62].  
 The physics behind flow cytometry, can be based on two equations:  
Equation 1.1: λ × ν = c  
Where λ = the wavelength in meters, ν =  frequency in cycles/s and c = the speed of light defined as 3 x 108 m/s. 
Equation 1.2: E = h × v  
Where E = energy in joules for one quantum of radiation and has a frequency of ν (cyces/s), h = Planck’s constant 
(6,626 x 10-34 J/s and ν =frequency in cycles/s.  
  Equation 1.1 demonstrates the relationship between frequency and wavelength. Visible 
light exists between the wavelength of 400 nm to 700 nm [61].  
Equation 1.2 demonstrates the energy which is related to the frequency of radiation [61]. 
  Atoms in a molecule can exist in different energy states, where ground state does not 
require additional energy to be achieved. Atoms can be excited out of ground state and into a 
higher state level provided that the correct amount of energy is absorbed [61] . Figure 1.13 
demonstrates how an atom can absorb energy and further emit energy of a different wavelength.  
 
Figure 1.13. Absorption of energy to excite an electron and the emission of light at another wavelength. 
Energy which is supplied from the laser, hv, excites a valence electron from a lower energy state (E1) to a higher 
energy state (E2). Emission of the absorbed energy, will follow when the valence electron is dropped from a high 
energy state (E2), to a lower energy state (E1) and will subsequently release energy, hv.   
Figure adapted from [61] and redrawn by Christina Skår Saghaug. 
 
1.4.2 Spectral overlapping and importance of compensation 
A fluorescent molecule, or a fluorochrome, bound to a cell will be excited when a laser hits it. 
A specific fluorochrome has a specific wavelength where the emission will be strongest. Still, 
different fluorochromes tend to have emission ranges falling into the same or share parts of a 
wavelength range. When this happens to two or more fluorochromes, it is termed “spectral 
overlap”. A cell can be stained with multiple fluorochromes, and spectral overlap is not possible 





  In order to remove or improve spillover, compensation can be used. Compensation 
makes it possible to subtract spectral overlap fractions and thus making the signals seen more 
reliable.  A compensation matrix can be made by singly staining beads separately with each of 
all the fluorochromes used in an assay. A flow cytometric analysis program can be used to make 
a compensation matrix, and by adding this to the cell analysis, the spectral overlap can be 
adjusted and subtracted.  
 
1.4.3 Fluorochromes  
In order to investigate surface receptors on cells, cytokines, viability and proliferation, a 
fluorocrome needs to be connected to the target in the cells. A fluorochrome can be conjugated 
to an antibody, and if the cell expresses the antigen (i.e. receptor or cytokine) for this antibody, 
it will bind. When a target in a cell cell is bound to a fluorochrome-conjugated antibody (FAB), 
the fluorochrome will be excited during flow cytometric analysis. The signal seen for 
fluorochrome stained cells will be at another wavelength than unstained cells [61] .   
  Fluorochromes are often distinguished into brightness levels according to how bright 
their fluorescence signal is. This is important to consider when making multicolor panels with 
a mixture of highly expressed and poorly expressed target. The brightest colors should be used 
for the poorly expressed targets. Cross-reactive binding of a fluorochrome can also occur, 
resulting in a higher non-specific background signal in the true negative cells [61].  
 
1.4.3.1 Titrations  
When a cell has been stained by a FAB adhering to it, it will be excited by a laser when analyzed 
in the flow cytometer. The signal from the stained cells can however overlap with the signal 
from the unstained cells.  
It is therefore necessary to maximize the specific-to-nonspecific binding, termed as signal-to-
noise ratio, meaning the optimal concentration of a fluorochrome. In order to find the optimal 
concentration for a fluorochrome, it should be titrated. By testing a dilution row of the FAB the 
most appropriate concentration of the FAB can be found,  good separation between the 
unstained and the stained cell populations can be calculated using mean fluorescence intensity 
(MFI). The MFI for the stained and unstained cells can be found. The MFI of the positive cells 
are divided on the MFI of the unstained cells, and the concentration giving the highest ratio, 






1.4.3.2 Fluoroscence minus one  
Fluoroscence minus one, or FMO, is a useful tool for the recognition of spectral overlap. When 
many different fluorochromes are used, the corresponding overlap between the emitting 
wavelengths will also increase.  
If a FMO control is made for a fluorochrome used in an experiment, leakage from other 
fluorochromes in the assay and autofluoresence into its detection channel, can be acknowledged 
[63].  FMOs can also be helpful for setting gates determining the threshold for positive and 
negative cells.  
 
1.4.3.3 Live/Dead discrimination  
Dead cells can be a problem when using flow cytometry. Dead cells go through several changes, 
where the cell membrane will become permeable. Dead cells have been shown to bind FABs 
non-specifically. In analysis looking for rare events, dead cells can contribute considerably to 
false positives, and exclusion of these cells is important [64].  
  Many different methods exists to monitor viability, and measuring membrane 
permeability gives a good indication of the percentage of dead cells in a population. Such a 
staining dye can for instance react with DNA, and will only bind to dying or dead cells due to 
failing membrane integrety. Figure 1.14 illustrates how a staining dye, LIVE/DEAD viability 
dye (Life technologies) binds to dead cells, but not to live cells.   
Figure 1.14: Demonstration of how a viability dye works.  
Dead cells with damaged cell membrane will be stained with the LIVE/DEAD dye, and can be separated from the 
live cells, which will not be stained using flow cytometry. Figure is inspired by [64].  
 
1.4.3.4 Proliferation monitoring by dye dilution 
Cells that recognize or get activated by an antigen can undergo clonal expansion, proliferation 





proliferation dye, known as Carboxyfluorescein di-acetate succinimidyl ester (CFDA) diffuses 
into the cells and are cleaved by intracellular esters forming carboxyfluorescein succinimidyl 
ester (CFSE). The CFSE bind irreversibly to intracellular amines and if the cell is proliferating, 
daughter cells will contain half the concentration of the dye. The corresponding signal in a flow 
cytometer for daughter cells, will be of a lower intensity. Generations of the cells can thus be 
counted according to how many peaks are shifted towards zero in the specter [61, 65].   
  Another proliferation dye PKH, is lipophilic and will bind non-covalently to the cell 
membrane and become partitioned in the membrane. The concentration of the dye, will be 
halved for daughter cells when this dye is used as well [65].  
  Figure 1.15 demonstrates how proliferation can be tracked when staining with a dye 
(CellTrace), which diffuses into the cells and has similar properties as CFSE, but has a different 
fluorescent specter. The cell generations can be counted, and the percentages of proliferation 
can be calculated.  
 
Figure 1.16 Proliferation tracking using flow cytometry. 
A flow cytometric plot of undividing cells and dividing cells. The boxes represent the generations. Drawn by 
Christina Skår Saghaug.  
1.4.4 Staining with fluorochromes 
1.4.4.1 Surface staining 
Fluorochrome-conjugated antibodies (FAB) made for surface receptors can be used to assess 
the main cell populations, (also called lineage) such as CD3, CD4, CD8 and CD19. Surface 
staining is also possible for many activation markers, which are up-regulated and expressed on 
activated cells. Surface staining makes it possible to isolate the cells of interest, and further look 
at i.e. activation and which proteins these cells produce. Lineage surface markers are often 





1.4.4.2 Intracellular staining  
Cells can also be stained intracellularly by using FABs. Cytokines produced inside a cell are 
often of particular interest, since their production is important for immune responses. The 
problem with cytokines is that after production they are released to the surrounding mileu. The 
Golgi apparatus is an organelle responsible for the production of proteins, such as cytokines. 
When staining intracellular components, it is crucial to add a protein transport blocker to “lock” 
the cytokines inside the Golgi apparatus, in order to be able to stain them [61, 63].  
  Since the cytokines are located inside the cell, the fluorochrome-conjugated antibodies 
need to get into the cell as well. This can be done by first fixating the cell (i.e. crosslinking of 
macromolecules and prevention from decay), followed by permeabilization where small pores 
are made in the cell membrane. In this way antibodies directed to cytokines can get inside the 
cells and bind to them.  
 
1.4.5 Building a multicolor panel 
If many fluorochromes are used together making up a multicolor panel, several considerations 
have to be taken into account, before the results can be trusted.  
  The optimal concentration for the desired fluorochromes have to be found by titration 
in order to separate the stained cells from the unstained cell population. The voltages used in 
the set-up will also be important, as these should be adjusted to avoid spectral overlap into other 
channels, and the unstained cell population should be distributed around zero in a flow 
cytometric plot.   
  Compensation have to be done to adjust spectral overlap, and if more color are used, 
more spectral overlap will occur. Compensation is therefore crucial in multicolor panels.
 Different clones of FABs are available, binding to different epitopes of their cellular 
target. Clones for the same target molecule have different characteristics regarding non-specific 
binding, affinity to their target and compatibility with staining procedures and reagents. Some 
clones can be damaged during fixation and permeabilization and it is crucial to test their 
functions if used in an assay that requires intracellular staining. Non-specific binding can 
happen with fluorochrome and give rise to false positives. FMO controls should therefore be 
included in a flow cytometric assay to see how the spectral overlap manifest in the channel 
where one fluorochrome is missing. Non-specific binding of rare event or markers of activation 
can also occur in an unstimulated cell population. The clone used for the fluorochrome should 
then be investigated, and several ones should be tested if in doubt of non-specificity.  





conjugated fluorochrome have a relatively bright staining index. Weaker fluorochromes can be 
used for targets being highly expressed, such as lineage markers.  
  The stimulation time for a cell population can also be important for multicolor flow 
cytometry. The targets of interest will have to be up-regulated on the cells in order to stain them. 
One should therefore provide an optimal stimulation period.   
  
1.5 Background for the present study  
 
1.5.1Why do research on Giardia lamblia?  
Giardia lamblia is an intestinal protozoan parasite giving rise to infection both in humans and 
animals worldwide. The clinical picture of Giardia varies from asymptomatic carriers to severe 
disease such as malabsorption syndrome. Even if the infection itself normally not result in 
serious disease and death, it can be a contributing cause to health problems.  
  Specific immune responses gained by Giardia, has generally been studied in mice, and 
acquired immunity have been seen in these models [55, 66]. The specific responses of T cells 
in humans have however not been well characterized. There are reasons to believe that various 
host responses against the parasite is both important for how the symptoms manifest and if the 
disease turns into chronic state or give rise to more serious complications such as malabsorption 
syndrome.  
  Human peripheral blood mononuclear cells (PBMCs) give an opportunity to investigate 
T cell responses in humans. Giardia-specific T cell responses have earlier been found using 
flow cytometric analysis [10]. These finding suggest that T cell responses should be 
investigated further and may be used to characterize Giardia-specific immunity. 
  A detailed insight into T cell responses can be investigated by using soluble proteins 
from Giardia trophozoites to stimulate PBMCs. Cytokines produced by CD4+ T cells and CD4+ 
effector memory T cells in early phases of stimulation combined with information of later 
proliferation and activation responses expressed by CD4+ T cells, can be investigated using 
flow cytometry. Correlation between how cytokines expressed by effector memory cells will 
affect or not affect later activation can give valuable knowledge regarding specific memory 
immune responses.  
  A better insight and understanding for the progress and the duration of a Giardia-
specific immune response in humans is important and needed for development of a protective 
vaccine.  The study is potentially of interest not just for Giardia, but also for the host-microbe 





  An improved understanding of the progress, and length of Giardia specific immunity in 
human beings will, and approaches as how to assess these, will assist further to understand 
underlying general mechanisms for how pathogens may or may not elicit symptomatic disease. 
Advanced medicine regimes in order to get rid of an infection can lead to decreased compliance 
and lead to resistance, and understanding immune responses is important to avoid this by 
develop a vaccine [36, 67]. 
1.5.2 Aims of the study  
An earlier flow cytometric study conducted [10], suggested that cellular immunity against 
Giardia could last up to five years. The surface markers CD25, CD26, CD45RO and HLA-DR 
were examined in this study in addition to the general proliferation on lymphocytes.         
  This project aimed to characterize Giardia-specific memory CD4+ T cell immune 
responses in recently infected individuals, by looking at early cytokine responses in the general 
CD4+ T cell population but also in the effector memory CD4+ T cell population, later surface 
activation in addition to proliferation of CD4+ T cells. 
Specific aim 1:  To develop two flow cytometric assays capable of measuring Giardia-specific 
T cell cytokine responses, as well as proliferation and activation markers was performed in this 
study.  
Specific aim 2. To test performance of these assays using a group of giardiasis exposed persons 
compared to low risk healthy controls.   
Specific aim 3. Given that Giardia specific immunological responses were seen in the flow 







2. Materials  
 
2.1 Giardia antigen preparation 
2.1.1 Origin of Giardia antigens 
In October 2013, Giardia antigens were sent to the Department of Clinical Science, University 
of Bergen, Bergen, Norway from the Department of cell and molecular biology, Uppsala 
University, Uppsala, Sweden. The laboratory work regarding growing trophozoites, harvesting 
and acquiring of the proteins in the sonicated lysates was done in Uppsala, Sweden. 
  
2.1.2 Harvesting, lysation and  sonication of  Giardia trophozoites 
Giardia  assemblage A (WB-C6, ATTC 50803) and B (GS/M, ATTC 50581)  trophozoites 
were grown in separate Diamond- and Keister medium (TYDK medium) supplemented with 
bile, supporting the methods of Keister [68], at a temperature of 37 °C.   
The trophozoites were collected from a 50 mL falcon tube with an 80 % confluence 
(approximately 5x106 cells) and washed 3 times in cold sterile PBS.   
The cells were harvested at 4 °C using centrifugation at 2500 rounds per minute (RPM) for 5 
minutes and re-suspended in 5 mL sterile PBS. The re-suspended cells were snap-freezed-
thawed in liquid nitrogen twice and sonicated (3 times for 30 seconds at 50 Watts). Membrane 
and cell debris were removed by centrifugation at 4 °C at 13000 RPM for 15 minutes. The 
supernatants containing Giardia soluble protein fractions were sent on dry ice to the 
Department of Clinical Science, University of Bergen, Bergen, Norway and stored in at – 70 
°C until further investigation. 
2.1.3 Concentrations of the Giardia soluble proteins  
The protein concentrations were measured in the received Giardia soluble proteins solutions. 
Measurement was done using the DIRECT DETECT™ system (EMD Millipore corporation, 
Billerica, MA, USA). The Giardia protein solutions were then diluted to 50 µg/mL in X-vivo 
medium and stored at -20°C1.   
  These Giardia soluble proteins, named SSA for Giardia assemblage A and SSB for 
Giardia assemblage B, were later used to stimulate peripheral blood mononuclear cells (PBMC) 
in order to elicit Giardia-specific T cell responses. The concentrations used for PBMC 
                                               






stimulation are shown in Table 2.1.  
  
Table 2.1: Concentrations of the two Giardia isolates used in the project and final concentrations used in 
stimulation culture.  The measured concentrations of the received solutions of Giardia proteins, the concentration 
of the stock solutions and the final concentration used to stimulate PBMCs. The sonicated supernatant proteins 





























Day one and six 
 
Day one and six 
 
2.2 Reagents for positive and negative controls  
Reagents used as positive controls were chosen depending on their stimulation capacity. 
Lipopolysaccharide (LPS) is a powerful macrophage activator, and macrophages can activate 
T cells [1].  Staphylococcal enterotoxin B (SEB) is classified as a superantigen and can 
stimulate more T cells than conventional antigens. SEB has a capacity to stimulate naïve CD4+ 
cells into proliferation [1]. Purified protein derivative (PPD) was used, as this antigen can 
stimulate T cells of previously vaccinated individuals [1]. Phorbol 12-myristate 13-acetate 
(PMA) and Ionomycin calcium salt (IC) were used in combination. PMA can diffuse directly 
through T cell membranes and activate cells without MHC presentation of antigens.   




                                               
2 Mean of two protein concentration measurements 






2.2.1 Reagents used for positive controls  
Positive controls were used in every experiment to ascertain cell responses.  Table 2.2 shows 
the reagents used for positive controls in the project.  
 
Table 2.2: Concentrations of reagents for the PBMCs stimulation and which assay they were used. 
Name of antigen reagents 
Stock concentration         
[mg/mL] 
Final concentration 
           [µg/mL] 
Assay 
 
Lipopolysaccharide (LPS),  




acetate (PMA)  
Chemical5  
 
Ionomycin calcium salt (IC), 
Streptomyces conglobatus6 
 
Purified protein derivate (PPD),  
Mycobacterium tuberculosis7 
 













































                                               
4 Sigma Aldrich, product number: L9516, 5mg dissolved in 10 mL sterile NaCl and stored at -20°C in aliquots. 
5 Sigma-Aldrich, product number: P8139, 1 mg, diluted in 1 mL DMSO and stored at -20°C in aliquots. 
6 Sigma-Aldrich. Product number I0634, 1 mg, diluted in 1 mL DMSO and stored at -20°C in aliquots. 
7 Statens Serum Institut, Copenhagen, Merida number: 3704627. 1mg/mL 1 mL test tubes stored at 4-8°C. 






2.2.2 Negative control  
 
Table 2.3: Cells in medium without stimulating agents was used as a negative control in this project 
Name of medium Application day Supplier 
X-vivo 15 with Gentamicin and 
Phenol red (MED) 
Day 1 and day 6 Lonza via BioNordika 
 
 
2.3 Solutions made or diluted in the laboratory  
 
Table 2.4: Solutions made or diluted for this project 
Solution Ingredients and storage 
Dulbecco’s Phosphate Buffered Saline (PBS) 
pH 7.4. Filtered for unsterile usage. 
Filtered and autoclaved for sterile usage. 
8 g NaCl + 1.44 g Na2HPO4 · 2H2O + 
 0.2 g KCl + 0.2 g KH2PO4 and adjusted up to 1 
L with Milli-Q water. Stored at 2-8°C 
Paraformaldehyde 2 % (w/v) in PBS. (PFA). 
Filtered before usage. 
2 g paraformaldehyde (Sigma-Aldrich P-6148) 
was added to every 100 mL PBS and heated to 
65 °C until dissolved. Fresh solution was made 
every 2 weeks. Stored at 2-8 °C 
Perm/Wash 1:10 dilution (PW). 
Filtered before usage. 
1 mL 10x Perm/Wash (BD Biosciences Franklin 
Lakes, New Jersey, USA) was added to every 9 
mL milli-Q water making a solution of 10 % 
Perm/Wash. Stored at 4 °C. Throughout the 
project, a fresh made solution was made for 
every new experiment. 
Brefeldin 5 mg/mL 
5 mg Brefeldin (Sigma-Aldrich, St. Louis, MO, 
USA) was dissolved in 1 mL Dimethyl sulfoxide 
(DMSO). Stored in aliquots at  
-20 °C. 
Serum 10 % in PBS 
550 µL of Pooled human serum, drawn the 
17.04.2008 (Infectious laboratory, Haukeland 
University hospital, Bergen, Norway), was 
diluted in 4950 µL PBS and stored at 4-8 °C. 







2.4 Kits used in the project  
 
Table 2.5: Purchased kits used in this project 
Kit name Supplier Catalog nr 
LIVE/DEAD Fixable Near-IR Dead cell Stain Kit 
(Dye coupled to APC-H7) 
Life Technologies L10119 
Anti-Mouse Ig, κ/Negative Control (FBS) 
Compensation Particles Set 
BD Biosciences 552843 
Anti-Rat and Anti-Hamster Ig κ/Negative Control 
Compensation Particles Set 
BD Biosciences 552845 
BD Cytofix/Cytoperm™ 
Fixation/Permeabilization Kit 
BD Biosciences 554714 
CellTrace™ Violet Cell Proliferation Kit (Dye 
coupled to the fluorochrome Pacific-Blue) 
Life Technologies C34557 
 
 
2.5 Equipment for cell harvesting and culturing 
 
Table 2.6 Tubes and plates used for cell harvesting and stimulation 
Equipment Supplier 
BD Vacutainer CPT Na-Heparin 8 mL BD Biosciences 
Centrifuge tube 15 mL Polypropylene Sarstedt 
Centrifuge tube 50 mL Polypropylene Sarstedt 












2.6 Fluorochrome-conjugated antibodies (FABs) 
 
Table 2.7: Overview of the FABs used in this project.   
All the antibodies and dyes used in this project were directly coupled to a fluorochrome. 
Antibody Clone Fluorochrome Isotype Concentration Supplier Catalog 
nr. 
CD3         UCHT1 Alexa Fluor® 700     M* IgG1, κ 500 µg/mL          Bio Legend            300424 
CD8a                RPA-T8      Brilliant Violet 711™   M* IgG1, κ        50 µg/mL             Bio Legend           301044 
CD4                        L200 PerCP-Cy™5.5              M* IgG1, κ         25 µg/mL        BD Biosciences       552838 
CD14                            M5E2 APC-H7                 M* IgG2a, κ        50 µg/mL        BD Biosciences      561384 
CD45RA               Hl100 Brilliant Violet 510™     M* IgG2b, κ        50 µg/mL            Bio Legend          304142 
CD45RO        UCHL1       Brilliant Violet 605™      M* IgG2a, κ         100 µg/mL            Bio Legend          304238 
CD26                                                      BAgb   PE M* IgG2a, κ                   50 µg/mL Bio Legend        302706 
CD25          M-A251                                    APC  M* IgG1, κ            1.5 µg/mL       BD Biosciences     555434 
HLA-DR                                                TU36 FITC M* IgG2b, κ        25 µg/mL      BD Biosciences      555560 
IL-17A                 BL168 Brilliant Violet 605™     M* IgG1, κ          50 µg/mL            Bio Legend          512325 
IL-10            JES3-19F1                                PE        R# IgG2a                 25 µg/mL          BD Biosciences     559330 
IL-4             MP4-25D2                                  APC    R# IgG1, κ             200 µg/mL                    Bio Legend 500812 
TNF-α                Mab11 Brilliant Violet 421™   M* IgG1, κ          100 µg/mL                  Bio Legend 502932 
IFN-γ                                                       B27 FITC M* IgG1, κ        50 µg/mL          BD Biosciences     552887 
CD197                       150503 PE-CF594               M* IgG2a           100 µg/mL        BD Biosciences     562381 
*M = mouse and #=rat  
 
2.7 Study population  
Two groups of people were recruited in this experiment in order to evaluate differences between 
a Giardia exposed group and a control group. All the individuals in the study had previously 
received BCG vaccine against tuberculosis. 
 
2.7.1 Giardia exposed group 
Fifteen consecutively identified adults with recent (last 26 months) symptomatic chronic or 
acute giardiasis were eligible for inclusion. The majority of these individuals were returning 
travelers. The infection was laboratory confirmed by routine light microscopy.  Participants in 






2.7.2 Low risk healthy controls  
 
Eleven age and sex matched controls with a low risk of ever having had giardiasis were eligible 
for inclusion. A low risk healthy control was defined as never having travelled to highly 
endemic areas (low and middle income countries), not drinking contaminated water in Bergen 
the Autumn 2004, or known previous giardiasis and having no relatives with known giardiasis 
in the past.   
Participants in the low risk healthy control group were given study IDs starting with LR.  
2.7.3 Exclusion criteria for both groups 
Exclusion criteria for all groups were age below 18 or above 70, known immunosuppression or 
ongoing treatment with immunosuppressive medication and autoimmune diseases. 
 
2.8 Instruments and incubator  
2.8.1 Flow cytometer 
BD LSR Fortessa™ Cell Analyzer (BD BioSciences, Franklin lakes, New Jersey, USA) was 
used to gather fluorescence properties of cells. 
2.8.2 Cell counting  
MUSE™ Cell Analyzer (Millipore Corporation, Billerica, USA) was used to count cell 
concentrations and to assess viability of freshly acquired PBMCs before culture stimulation. 
2.8.3 Centrifuge  
 
The centrifuge used for both tubes and plates was a Centrifuge 5810 R (Eppendorf, Hamburg, 
Germany). 
2.8.4 Eppendorf centrifuge 
The centrifuge used for spinning down aggregates in FAB mixes was a Centrifuge 5417 C 
(Eppendorf, Hamburg, Germany). 
2.8.5 CO2 incubator 
For the stimulation of PBMCs with antigens, a CO2 incubator model MCO-15AC (Sanyo 







2.9 Computer software 
2.9.1 Word  
The project was written and edited using Word 2013 (Microsoft corporation, Redmond, 
Washington, USA). 
2.9.2 Excel  
Graphs and histograms were made using Excel 2013 (Microsoft corporation, Redmond, 
Washington, USA).   
 
2.9.3 Flow cytometer software  
For acquiring data from cell samples, BD Facsdiva version 8 (BD Biosciences, Franklin Lakes, 
New Jersey, USA) was used. The data was collected as FCS-files, and was transferred to other 
computers for further investigations. 
2.9.4 Flow cytometric analysis program  
Analysis of FCS-file data from BD Facsdiva was done in FlowJo version X10 (Tree star Inc., 
Ashland, Oregon,USA).   
2.9.5 Statistical analysis program  
To assess statistical significance of comparisons between the groups and responses, Mann-
Whitney U non-parametric test, linear regression using Pearson’s correlation coefficient test, 
Fisher’s exact test and non-parametric Kruskal Wallis test were applied.  
The Statistics software used was IBM SPSS 21 (IBM corp, Armonk, New York, USA).  
 





3. Methods  
 
3.1 Recruitment of individuals  
3.1.1 Recruitment of healthy volunteers for method development  
Staff and students working at the University of Bergen or Haukeland University hospital were 
asked to donate blood for the purpose of method development and flow cytometric testing. 
Some of these healthy volunteers agreed to donate blood several times for method testing, and 
to serve as low risk healthy controls in the study.  
3.1.2 Recruitment of participants to the study; healthy low risk controls and 
giardiasis exposed persons 
Two groups were considered to be relevant for testing the assay. Persons exposed to Giardia, 
and persons with low risk of ever having had giardiasis.  The exposed group were recruited 
through e-mail, phone call or both, based on data from the microbiological laboratory at 
Haukeland University Hospital. Low risk controls were recruited through the research group’s 
network, and among students, hospital and laboratory staff by direct contact.   
  Both groups had to answer a set of questions in a Case Report Form (CRF), before the 
participants could be included/excluded in the study. The CRF contained information regarding 
exclusion criteria, the nature of the Giardia infection, giardiasis risk for low risk healthy 
controls, abdominal symptoms the past 2 weeks, regular medication, in addition to sample 
related data. The CRF used in this project is attached in Appendix A. An informed consent 
regarding participation, storage of samples and storage of personal information, had to be filled 
in and accepted by the participants. The informed consent form is attached in Appendix B. 
  During the study period of two months, fifteen out of eighteen available Giardia 
exposed individuals accepted to participate in the study. Eleven healthy controls with a low risk 
for ever having had giardiasis were recruited. One control had to be excluded due to later 
information about travel to a Giardia endemic area. Thus, 10 low risk healthy controls was 
included in this study. 
  The participants were older than 20 and younger than 70 and all turned out to be 
Caucasians (ethnical Norwegian). All of the participants were tested for Giardia by PCR.
  
 





 3.1.3 Investigation of ongoing giardiasis 
To determine if participants were Giardia infected at the time of the study, a stool sample was 
collected from all participants and analyzed for presence of Giardia by polymerase chain 
reaction (PCR). The PCR assay was performed by other laboratory staff9.  
The Giardia status of participants had to be known to exclude low risk healthy controls and to 
be able to treat individuals with ongoing infection.  
  If the PCR test was positive, the individuals were treated with metronidazole 400-500 
mg three times a day for 7-10. A second line treatment, albendazole 400 mg in combination 
with 250 mg metronidazole two times a day for seven days, was used in order to get rid of 
infection.  
 
3.2 Collection of peripheral blood mononuclear cells (PBMCs) 
Human blood contains many different cells and in order to isolate PBMCs, BD Vacutainer® 
CPT™ Tube with Na+/heparin (CPT) was used. These tubes contain a polyester gel and a dense 
solution and cells in human blood can be separated by centrifugation due to differences in 
density.  The human blood would be segregated into different layers with plasma on the top 
followed by mononuclear cells and platelets. The dense solution and polyester gel separated the 
granulocytes and red blood cells, which would be at the bottom of the tube after centrifugation. 
Figure 3.1 demonstrates a CPT tube filled with blood before and after centrifugation. 
 
Figure 3.1: CPT tube before and after centrifugation.  
Adapted from manufacturers protocol [70].  
 
                                               
9 Done by medical students Martin Kristiansen and Torunn Hjøllo 





3.2.1 Procedure of cell harvesting  
 
The procedure of cell harvesting was done in sterile environment using sterile equipment and 
safety bench. Before blood samples were drawn from the recruited participants or volunteers 
for method development, one 50 mL size conical centrifuge tube with cap was filled with 20 
mL sterile PBS. If cold PBS was used, it had to reach room temperature (RT), approximately 
20°C, before the cells were added. One 50 mL centrifuge tube was used for each participant 
and was marked with study ID.  
  Blood was collected into 4 CPT tubes per participant using standard venipuncture 
technique. The CPT tubes had to be inverted 10 times to ensure good mixing of blood and 
chemicals inside the tube. The CPT tubes were labeled with study number. All the blood 
sampling was done in the laboratory for infectious diseases. 
  The time from collection until CPT tube centrifugation did not exceed two hours. The 
CPT tubes were inverted 10 times immediately prior to centrifugation. Centrifugation of the 
tubes was done at 1800 Relative Centrifugal Force (RCF) at RT for 20 minutes.  
  Collection of the PBMCs was done immediately after centrifugation. The plasma layer 
above the PBMC layer was pipetted away and discarded in a biohazard container. The PBMC 
layer was then collected using a sterile pipette and tips and transferred into the previously filled 
50 mL centrifuge tube with RT sterile PBS. All the PBMCs in the CPT tubes from the same 
participant were added into the same 50 mL centrifuge tube. The tube was then filled with PBS 
up to a final volume of 50 mL. The tube was capped and the contents mixed by inverting the 
tube 5 times.  
  The cells were then pelleted by centrifugation for 15 minutes at 300 RCF at RT. The 
supernatant was decanted carefully without disturbing the cell pellet. The cell pellet was re-
suspended in the remaining volume in the centrifuge tube, and transferred to a 15 mL conical 
centrifuge tube using a pipette. To obtain all the cells from the 50 mL centrifuge tube, 1 mL 
PBS was added, gently rotated, and transferred to the 15 mL centrifuge tube. The 15 mL 
centrifuge tube was filled to a final volume of 15 mL with PBS. The centrifuge tube was capped 
and inverted 5 times.  
  The tube was centrifuged for 10 minutes at 300 RCF at RT and the supernatant was 
decanted carefully. The cells were re-suspended in the residual volume. X-vivo medium was 
added to the 15 mL tube to a final volume of 5 mL.  
These PBMCs in medium were in the first period of the project used to develop the flow 





cytometric method for characterizing human T cell responses against the enteric protozoan 
parasite Giardia lamblia. In the last period of the project, PBMCs obtained by the same protocol 
were used in the optimized flow cytometric assay to analyze human T cell responses. 
  
3.3 Method development  
3.3.1 Titrations of the fluorochrome conjugated antibodies and dyes  
To determine the most suitable concentration of the fluorochrome-conjugated antibodies 
(FABs) and dyes, a dilution series was done. Titrations were done on freshly harvested or 
stimulated cells. To titrate intracellular antibodies directed towards cytokines, 4 hours 
stimulation with PMA and IC was sufficient, while the proliferation and surface activation 
markers were stimulated over a longer period of time (6 days) to ascertain positive cells for 
these markers.  
  The washing of cells in tubes was always done by centrifugation at 350 RCF for 5 min. 
at RT. Cells in plates were washed by centrifugation at 450 RCF for 5 min. at RT and after 
permeabilization/fixation cells were washed by centrifugation at 600 RCF for 5 min. at 4 °C. 
The supernatants were discarded by decanting for tubes and flicking for plates.  
 
3.3.1.1 Protocol for titration of CD3, CD4, CD8a, CD14 and LIVE/DEAD 
Freshly harvested PBMCs from 3.2.1, in the 15 mL centrifuge tube, were washed 2 times with 
PBS. A dilution series for each fluorochrome was done using Eppendorf tubes. A 2-folddilution 
series with final staining concentrations of 5.0 µL, 2.5 µL, 1.25 µL, 0.63 µL and 0.31 µL FAB 
per 100 µL cell solution was used for CD3, CD4, CD8a and CD14. To the first Eppendorf tube 
in the dilution series, 90 µL PBS was added and 10 µL of a FAB. The four other Eppendorf 
tubes in the dilution series were filled with 50 µL PBS. The dilution was done by taking 50 µL 
from the first tube in the series, mixing it with the next and take 50 µL of this and transferring 
it to the next tube. The remaining 50 µL from the dilution series was discarded. 
  The dilution series of LIVE/DEAD was done likewise, but first 50 µL of Dimethyl 
Sulphoxide (DMSO) was added to the LIVE/DEAD vial and mixed. 1 µL of this dye was added 
to 999 µL PBS in an Eppendorf tube. 500 µL PBS was added to the other Eppendorf tubes  
(3 Eppendorf tubes in total).   
  The cells were spun down by centrifugation and re-suspended in 1150 µL PBS. 50 µL 
of this cell suspension was added to the wells of a 96-V-wells plate giving columns of cells for 
each fluorochrome. 50 µL of each of the fluorochromes in the dilution series was added to the 





cells. The cells were incubated with the FABs or the dye for 30 min. in the dark at room 
temperature. The cells were washed two times with PBS. The cells were transferred into marked 
flow tubes, with a final volume of 300 µL before analysis was done on the flow cytometer the 
same day.     
 
3.3.1.2 Protocol for titration of TNF-α, IFN-γ, IL-17A, IL-10, IL-4, CD197 and CD45RA 
Freshly harvested PBMCs from 3.2.1 with a volume of 5 mL in a 15 mL centrifuge tube was 
placed in a CO2-incubator over-night. The next day the cells were stimulated with an antigen. 
  The stimulation was done by thawing 4 µL frozen PMA and 40 µL IC and dilute them 
with 9996 µL PBS and 3960 µL PBS, respectively, in 15 mL centrifuge tubes. The two 
stimulation antigens were added to the cell suspension (280 µL of each), making a final 
concentration of 0.02 µg/mL of PMA and and 0.5 µg/mL of IC. Brefeldin A was also added 
(11.2 µL) in the final concentration of 10 µg/mL. The cells were put back in the CO2 incubator 
for an incubation time of six hours.  
  After the incubation time, the cells were washed two times with PBS. The stimulated 
cells were re-suspended in 1500 µL and 50 µL of this cell suspension was transferred to a 96 
V-wells plate making 7 columns of cells, one for each fluorochrome. A 2-fold dilution series 
was done for CD197 and CD45RA by adding 10 µL of each fluorochrome into 90 µL PBS to 
the first Eppendorf tube in the dilution series and dilute as stated in 3.1.1.2. Two of the cell 
columns in the plate were used for the two surface markers CD197 and CD45RA, where 50 µL 
staining solution from the dilution series was added to the wells. At the same time, all of the 
cells were stained with the optimal concentration for CD3 followed by an incubation in the dark 
for 30 minutes at RT. The cells were washed two times by centrifugation. Before the titration 
of the cytokines could be carried out, the cells had to be permeabilized and fixated. This 
procedure is stated in 3.6.1.3. The cells were kept on ice further on.   
  A 2-fold dilution series was used for TNF-α, IFN-γ, IL-17A, IL-10 and IL-4. To the first 
Eppendorf tube in the dilution series, 80 µL PW was added and 20 µL of a FAB. The dilution 
series was done the same way as stated in 3.1.1.2.  
  The cells were incubated with the intracellular FABs for 30 min. in the dark at 4°C. The 
cells were washed two times with PW and two times with PBS. The cells were re-suspended in 
PBS and transferred into marked flow tubes, making a final volume of 300 µL. Analysis was 
done the same day on the flow cytometer.    
 





3.3.1.3 Protocol for titration of CD25, CD26, CD45RO, HLA-DR and CellTrace 
Freshly harvested PBMCs from 3.2.1, in the 15 mL centrifuge tube, were used for the titrations.  
196 µL cells per well was transferred to a 96 V-wells plate, making a total of 4 columns with 5 
rows, suitable for a 2-fold dilution series.  
  1 mL of cell suspension was left in the centrifuge tube, and was used for the CellTrace 
titration. This was done by adding an excess of 500 µL medium to the centrifuge tube, mix the 
contents and divide the suspension into three 15 mL centrifuge tubes, with 500 µL cell 
suspension in each tube. The CellTrace staining dye had to be mixed before labeling of cells 
could be done. The mixing was done by adding 20 µL DMSO to a CellTrace vial (from 
CellTrace™ Violet Cell Proliferation Kit) and 2 µL of this fluorescence dye was mixed with 
the first cell suspension, 1 µL and 0.5 µL was added to the other ones in the dilution series. The 
cells were incubated for 10 min in the dark at RT. The cells were washed two times by 
centrifugation at 350 RCF for 5 min. at RT by filling the tubes with medium. The cells were re-
suspended in 196 µL medium and transferred to the same 96 V-wells plate with the previously 
added cells.   
 8 µL of SEB (Sigma-Aldrich, concentration 500 µg/mL), was diluted in 72µL PBS and 
4 µL of this antigen mix was added to all the wells, making a final concentration of 0.1 µg/mL. 
The plate was placed in a CO2-incubator for 6 continuous days.  
  After the antigen stimulation, the cells were washed two times out of the stimulation 
medium with PBS. The cells were re-suspended in a total volume of 50 µL.  
  A dilution series for each fluorochrome was done using Eppendorf tubes. A 2-fold 
dilution series was used for CD25, CD26, CD45RO and HLA-DR. To the first Eppendorf tube 
in the dilution series, 90 µL PBS was added and 10 µL of a fluorochrome. The dilution was 
done the same way as stated in 3.3.1.1. The CellTrace labeled cells were at the same time stained 
with the optimal concentration of CD3. The cells were incubated for 30 min in the dark at RT. 
The cells were washed with PBS two times before they were transferred into marker flow tubes, 
making a final volume of 300 µL and analyzed the same day on the flow cytometer.  
3.3.1.4 Finding the optimal concentrations from the titrations 
The optimal concentrations used in this assay for a FAB or a dye, were based on the results 
from titrations. The MFI for a positively stained cell population was found in the flow 
cytometric analysis program. The MFI for a positive cell concentration was divided by the MFI 
for a negative population, and would give a ratio. The highest ratio would mean the maximum 
signal-to-noise ratio, and thus the best separation between the two cell populations.  
 





3.3.2 Compensation and voltage settings 
Before compensation was done, different voltages were tested for each of the fluorochromes. 
The testing was done by checking the spectral overlap into other channels using histograms for 
all the parameters used, in the flow cytometer software BD Facsdiva.  The negative stained 
beads should lie around zero for the optimal voltage as well.  
  A compensation matrix was obtained using Anti-Mouse Ig, κ/Negative Control (FBS) 
Compensation Particles Set and Anti-Rat and Anti-Hamster Ig κ/Negative Control 
Compensation Particles Set. The different FABs were mostly from mouse, but a few were 
produced in rat. The relevant type of compensation beads for each fluorochrome were used in 
order to get a positive staining. CellTrace labeled PBMCs were used when obtaining the 
compensation matrix where Celltrace was included.  
  Flow tubes were used when the compensation was carried out and one flow tube was 
designated to each of the FABs or dyes. The beads from the Compensation Particles set were 
vortexed and one drop of the positive control and one drop of the negative control was added 
to every flow tube. For the CellTrace compensation, cells labeled with CellTrace and unstained 
cells were added to a flow tube.  
  The beads were washed with PBS two times. The optimal concentration for each of the 
fluorochromes found in the titrations were used. The beads were incubated 30 minutes in the 
dark at RT and washed one time and re-suspended in 300 µL PBS.  
  The compensation beads were run on the flow cytometer the same day as the staining 
was carried out.  
 
3.3.3 Fluorescence minus one (FMO) 
FMOs were done for all the experiments involving recruited individuals to the study. The FMOs 
were done as a quality control for the gating strategy and also to determine spectral 
overlap/spill-over from other channels, into the channel where one fluorochrome was missing. 
 
3.3.3.1 FMOs for cytokines  
Cytokines are dim markers and few positive cytokines can be seen in a large cell population. It 
is important to exclude false positives, and FMOs can be used to guide gating. 
When an intracellular staining was done, FMO staining cocktails where made for each of the 
cytokine FABs. This was done by adding all the FABs, except the one in question.  
 





3.3.3.2 FMOs for surface markers  
When surface activation markers FABs were added to the wells, FMO staining cocktails were 
added as well. This was done by adding all the surface activation FABs, except the one in 
question.   
 
3.3.4 Exploring CD8+ responses 
CD8+ and CD4+responses were investigated by testing two fluorochrome panels where perforin, 
CD69 and CD107a was included (information in Appendix D).  
CD69 and perforin were titrated the same was as CD45RA and CD197, while CD107a was 
titrated using six days of stimulation where this FAB was added in a dilution series to PBMCs 
in the last six hours of stimulation and a cytokine transport blocker protein, monensin 
(Appendix D), was added to the wells during the staining. These FABs were tested the same 
way as 3.6.  
 
3.5 Cell counting, adjusting cell concentrations and stimulation times 
3.5.1 Cell counting 
Cell counting was done by diluting 20 µL of cell suspension from freshly harvested cells with  
380 µL or 780 µL MUSE™ count and viability kit (EMD Millipore corporation, Billerica, MA, 
USA) . The dilution factor used was determined by the cell pellet size during harvesting. The 
counting was carried out using MUSE™ Cell Analyzer according to core facility’s instructions.
  
3.5.2 Cell concentrations  
According to the cell count, the PBMC stock solution had to be separated into two tubes with 
two different concentrations. One concentration was used for the day one assay and another one 
for the day six assay.  In the day one assay, concentrations of 6-10x105 cells/mL were used. In 
the day six assay concentration of 2x105 cells/mL were used. The total volumes needed for the 
assays were calculated with regard to how many wells were used in each setup (duplicates or 
triplicates and extra wells for FMOs). 
3.5.3 Stimulation time and antigens  
3.5.3.1 Plates and stimulation time for day one assay 
Two 96 V-wells plates, one for the day one assay and one for the day six assay, were prepared 
with 100 µL of the different antigens. For day one, SSA, SSB, PPD and LPS were put into wells 
in twice the final concentration needed. 100 µL MED was added to the negative control wells 





in addition to the wells designated PMA/IC, since the addition of these antigens was done the 
next day. 100 µL cell suspension for day one was added to each well with the antigens and 
controls. The 96 V-wells plate was placed in a CO2 incubator at 37°C for stimulation for period 
of 24 hours. The day six cells had to be labeled with CellTrace before incubation with antigens. 
 Figure 3.2 demonstrates a typical set up for the 96-V wells plates with antigens and 
negative controls used in day one and day six assays.  
  
Figure 3.2: Stimulation plates for day one and day six assay.  
Antigens used for the stimulation of PBMCs. These plates represents an experiment using 2 individuals from each 
group (Ag and LR) and triplicates used for each antigen and two triplicates for the negative control, MED. 
 
3.5.3.2 Labeling day six assay PBMCs with CellTrace and stimulation time 
The volume of the cells in medium with the concentration of 2 x 105 cells/mL was adjusted to 
1 mL.   
  CellTrace was mixed by thawing the two components in the CellTrace™ Violet Cell 
Proliferation Kit at RT. CellTrace is sensitive for light, and the light was turned off in the safety 
bench when doing the labeling. The working solution of CellTrace staining dye was made by 
adding 10 µL of DMSO to the CellTrace vial and vortex it. Labeling was carried out by adding 
one drop of 100 µL PBS to the inside of the tube, with cells, while the tube was held slantingly.  
Then 2.1 µL of CellTrace was added to the PBS droplet, the tube was raised to an upright 
position and immedialtey vortexed, thus rapidly mixing the dye evenly with cells. The cells 
were then incubated in the dark for 10 minutes at RT. Labeling of CellTrace was inspired by 
[71].  
  The tubes were filled up with medium and washed. The supernatant was decanted, the 
cells re-suspended and the washing was repeated once, and cells were re-suspended in the final 
volume needed to fill duplicate or triplicate wells in a 96 V-wells plate. For the day six assay, 





100 µL SSA, SSB, PPD and SEB had been added to wells in twice the final concentration 
needed. 100 µL MED was added to the negative control wells (the 96 V-wells plate in shown 
in Figure 3.2). 100 µL of labeled PBMC suspension was added to each well. The 96 V-wells 
plate was placed in a CO2 incubator at 37°C for 6 consecutive days.  
 
3.6 The two different assays looking at Giardia-specific immune 
responses 
Both of these assays were developed combining several other methods [61, 63, 65, 72-76], 
optimizing and validating results along the way. Figure 3.3 shows a flow chart of the two assay 
protocols combined.  
 
3.6.1 Day one assay protocol  
3.6.1.1 Washing the cells out of stimulation media and viability staining 
18 hours into the stimulation for the 96 V-wells plate for day one, the plate was taken out of the 
CO2
 incubator, placed in a sterile laminal Air Flow bench. 11.2 µL of PMA and 11.2 µL of IC 
(made  as stated in 3.3.1.2)  were added to the positive control wells. Brefeldin A was diluted 
1:10 and added to all wells in a final concentration of 10 µg/mL, and the plate was put into the 
CO2 incubator for another 6 hours, making the total stimulation period 24 hours long. 
  After the incubation, the cells were pelleted by centrifugation and re-suspended in PBS. 
The duplicates or triplicates of each participant were gathered into two columns, where one 
column served as stained cells and one as unstained cells. More cells were transferred into the 
column representing the stained cells. The cells were washed two times with PBS.  
  Viability staining was done by using Near Infrared dye (LIVE/DEAD). One vial of the 
fluorescent reactive dye (Component A) and the vial of anhydrous DMSO (Component B) was 
brought to RT before the caps were removed. 50 µL of DMSO was added to the vial of reactive 
dye. The contents were mixed and it was visually confirmed that all had been dissolved. The 
solution of reactive dye was used within a few hours of preparation. The remaining solution 
was kept in aliquots in a freezer (-20°C) for a maximum of 2 weeks.  
  1 µL of LIVE/DEAD was mixed with 999 µL PBS. 30 µL of this solution was added to 
the wells containing 30 µL cell suspension and mixed. The cells were incubated in the dark at 
RT for 30 min. The wells were filled up with PBS and washed twice. The cells were placed on 
ice after the last washing step and the temperature in the centrifuge was adjusted to 4°C. 
  





3.6.1.2 Blocking the Fc Receptors and surface staining  
Blocking of Fc Receptors with serum was used in order to reduce nonspecific binding of 
fluorescent staining. Before staining with FABs the PBMCs were incubated with 50 µL 10 % 
normal human serum in PBS at 4°C for 15 min. The cells were washed two times out of the 
serum media, and re-suspended in the residual volume.  
  A staining cocktail with all the surface marker FABs (CD3, CD4, CD8a, CD14, 
CD45RA and CD197) was made in an Eppendorf tube using PBS as staining media. All the 
FABs were added in double concentrations needed according to titrations The mix was spun 
down in an Eppendorf centrifuge at 14 000 RPM for 1 minute in order to let FAB aggregates 
fall to the bottom of the tube.  
  30 µL of the staining mix was added to the wells containing 30 µL of cells. The cells 
were incubated at 4°C in the dark for 30 minutes. The wells were filled up with PBS and washed 
two times. 
3.6.1.3 Fixation, permeabilization, intracellular staining  and analysis  
FABs have to get inside the cells to bind to cytokines. Fixation and permeabilization was done 
prior to intracellular staining was carried out. The fixation in the present study was done by 
adding 100 µL of Fix/Perm solution to all the wells, mix the cell suspensions, and incubate for 
20 minutes at 4 °C. The permeabilization was done by using PW as the washing media after 
fixation. The wells were filled with PW and washed two times. The cells were kept in PW after 
fixation and in the consecutive washing after staining, as PW is a reversible permeabilization 
agent.   
  The intracellular FABs (TNF-α, IFN-γ, IL-17A, IL-4 and IL-10) were added in double 
concentrations needed, according to titrations, to an Eppendorf tube containing PW, making a 
staining cocktail. The tube was spun down in an Eppendorf centrifuge at 14 000 RPM for 1 
minute in order to let FAB aggregates fall to the bottom of the tube.  
  30 µL of intracellular FAB cocktail was added to 30 µL cell suspension and incubated 
for 30 minutes at 4°C in the dark. FMOs for all the cytokine FABs was done by mixing a FAB 
cocktail including all FABs except the one to be controlled. After the staining incubation, the 
wells were filled up with PW and washed two times. Two additional washes were done with 
PBS before filling the wells up to a final volume of 250 µL. The final volume in each well was 
based on the requirements of the accessory plate reader during analysis on the flow cytometer 
done same day.  
 





3.6.2 Day six assay protocol  
3.6.2.1 Washing the cells out of stimulation media and viability staining 
After six days of incubation, the cells were taken out of the CO2 incubator and the cells were 
washed out of the stimulation media two times with PBS. The cells were pelleted by 
centrifugation and re-suspended in PBS. The duplicates or triplicates of each participant were 
gathered into two columns, where one column served as stained cells and one as unstained cells. 
More cells were transferred into the column representing the stained cells. The cells were 
washed two times with PBS.  
  Viability staining was the done by using Near Infrared dye (LIVE/DEAD). The 
previously mixed solution from day one was used on day six. The vial with the dye had to gain 
RT before it was used. 1 µL of LIVE/DEAD was mixed with 999 µL PBS. 30 µL of this solution 
was added to the wells containing 30 µL cell suspension and mixed. The cells were incubated 
in the dark at RT for 30 min. The wells were filled up with PBS and washed twice. The cells 
were placed on ice after the last washing step and the temperature in the centrifuge was adjusted 
to 4°C.   
 
3.6.2.2 Blocking the Fc Receptors and surface staining  
The blocking of the Fc receptors were done by incubating the cells with 50 µL 10 % normal 
human serum in PBS at 4°C for 15 min. The cells were washed two times out of the serum 
media and re-suspended in the residual volume.  
  The preparation of all the surface marker FABs was done by adding all the staining 
antibodies (CD3, CD4, CD8a, CD14, CD25, CD26, HLA-DR and CD45RO) in double 
concentrations needed, according to titrations, to an Eppendorf tube containing PBS, making a 
staining cocktail. The mix was spun down in an Eppendorf centrifuge at 14 000 RPM for 1 
minute in order to let FAB aggregates fall to the bottom of the tube. 30 µL of the staining mix 
was added to the wells containing 30 µL of cells. FMOs for the CD25, CD25, HLA-DR and 
CD45RO FABs were stained by a FAB cocktail including all FABs except the one to be 
controlled. The cells were incubated at 4°C in the dark for 30 minutes. After the staining, the 
wells were filled up with PBS and washed two times.  
 
3.6.2.3 Fixation with paraformaldehyde and analysis 
Fixation was done after the second wash with PBS by adding 100 µL 2 % Paraformaldehyde in 
PBS (PFA) to 100 µL cell suspension, making a final concentration of 1 % PFA. The suspension 
was mixed and incubated 30 minutes on ice. 50 µL PBS were added to all the wells to a final 





volume of 250 µL.  The final volume in each well was based on the requirements of the 
accessory plate reader during analysis on the flow cytometer done the same day.  
  
 
Figure 3.3: Flowchart demonstrating the workflow steps in the day one and the day six flow cytometric 
assays used in the project. The two different assays have some common protocol steps, but differ due to the 
investigation of different cell markers.  
  





3.7 Analysis using Flow cytometer BD LSR Fortessa  
 
3.7.1 Setting up flow cytometer  
A Cytometer Setup and Tracking (CST) was always done before a flow cytometric analysis 
took place. The CST was done according to instructions given by the core facility responsible 
for the flow cytometers. The CST was done as a quality control to assess function and day-to-
day variations of the flow cytometer. The delay on the lasers, trigger on the Fluorescence was 
noted, and flow cytometric analysis could be done if the CST passed.  
  Before using the plate reader, a washing step with a clean plate filled with Milli-Q water, 
FACS rinse solution (BD Biosciences) and FACS clean solution (BD Biosciences) was done to 
avoid remnants and debris in the flow cytometer.  
 
3.8 Flow cytometric analysis using FlowJo 
3.8.1 Gating strategy for day one assay  
FCS-files from the flow cytometer was transferred to a computer and the compensated 
parameters were analyzed. The cells were gated using FlowJo analysis program. The gating of 
cell populations from the day one assay, was done as shown in Figure 3.4.  
 
 
Figure 3.4: Cell gating for day one assay  
 A: The lymphocytes were gated first using SSC-A vs. FSC-A, followed by single cells gating using FSC-A vs. 
FSC-H. The CD3+ cells were gated and dead and CD14+ cells were excluded by plotting CD3 vs. LIVE/DEAD. 
Next the CD4+ cells were found plotting CD4 vs. CD 8. The CD4+ population was further investigated, plotting 
CD197 vs CD45RA, and the Effector memory CD4+ cells could be found.   
B: Cells positive for IFN-γ, TNF-α, IFN-γ and TNF-α, IL-4, IL-17A and IL-10 was gated from the effector memory 
CD4+ T cells.  
 





3.8.2 Gating strategy for day six assay 
The cell gating done for day six assay can be seen in Figure 3.5. The lymphocytes gated on day 
six were generally more blastic and had larger size compared to day one lymphocytes.  
 
Figure 3.5: Cell gating for day six assay  
The lymphocytes were gated using SSC-A vs. FSC-A. Next the single cells were gated using FSC-A vs. FSC-H. 
The CD3+ cells were found and dead and CD14+ cells were excluded by plotting CD3 vs. LIVE/DEAD. Next the 
CD4+ cells were found plotting CD4 vs. CD 8. CD25+CD26++ were found plotting CD4+ cells in a CD25 vs. CD26 
plot. HLA-DR+CD45RO+ were found plotting CD4+ cells in a HLA-DR vs. CD45RO plot.  Quadruple positive 
cell for all the four surface markers were gated, combining the two gates with CD45RO+HLA-DR+ cells with 
CD25+CD26++ cells (not shown in Figure). The proliferating subset of CD4+ cells were found plotting CellTrace 
vs SSC-A. 
 
3.9 Data analysis  
Data analysis was done by transferring flow cytometric data to excel. The percentages of the 
responses in the day one and day six assays in the various stimulation media were adjusted for 
the background responses in the negative control, medium. If the percentages were negative in 
stimulation media, it was corrected to zero. This was done done to ensure that background 
signals did not contribute to the responses seen for SSA and SSB, and also for the positive 
controls. 
  The data was transferred to SPSS version 21 for statistical testing could be done. 
Differences in cytokine producing cells, in cell activation and proliferation between the Giardia 
exposed group and the low risk healthy control group, were investigated by a 2-tailed Mann-
Whitney U test. To investigate demographical differences between the groups, Fisher’s exact 
test was done for categorical variables and non-parametric method with and Kruskal Wallis test 





was done for continuous variables. Correlation between responses was done using linear 
regression with Pearson’s correlation coefficient. P-values < 0.05 were considered to be 
statistically significant.   
 
3.10 Rare events in flow cytometry 
Cytokine producing cells are rare events, and it is important to have enough cells in the final 
analysis to detect these cells with flow cytometry. 
If a cell subset i.e. consists of 5 %, or less, the number of cell required to collect can be 
calculated following equations:   
Equation 3.1: SD = √𝑟  
Where SD = standard deviation and r = positive rare events.  
Equation 3.2: CV = 100/√𝑟  
Where CV = coefficient of variation and r = positive rare events.  
 
These equations can be combined giving:  
Equation 3.3: r = (100/CV)2  
 
If a CV value of 5 % is adequate and the cell population of interest comprise 5 % the entire cell 
population, following equation 3.3, 400 positive rare events have to be collected by flow 




 x 100 % = 8000 events have to be acquired. If a subpopulation comprise 0.1 % of a cell 
population, 400 000 events have to be collected to give a CV of 5 %. The more rare an event 
is, the more cells have to be used. This can provide difficulties, because unlimited number of 
PBMCs cannot be drawn from an individual. A higher CV should therefore be accepted if the 
number of cells required is unattainable [61].  
 
3.11 Ethical considerations and funding  
The pilot study involving human subjects was approved by the Regional Committee for Medical 
Research Ethics and performed in correspondence to the Declaration of Helsinki. Participation 
was voluntary and the recruited individuals could withdraw at any time without giving any 
consent.  
Blood sampling used in the study was not associated with critical complications. A small 





compensation was given to participants in order to cover the costs of travel and time. The 
sampling, participant compensation, laboratory reagents and analysis were covered by project 
grants from the Western Norway Regional Health Authority and the Department of Clinical 
Science, University of Bergen. If supplementary pathological findings were discovered, a 



















4.1 Method development 
4.1.1 Setting up a flow cytometric multicolor fluorochrome panel 
4.1.1.1 Titrations of the fluorochrome-conjugated antibodies or dyes used in the project 
All the fluorochrome-coupled antibodies (FABs) or dyes had to be titrated before the optimal 
concentrations for cell staining could be found. The lowest concentration possible, which at the 
same time provided a good separation of the positively stained cells from the negative ones, 
was used.  
  To find the most suitable concentration of each FAB, results were analyzed in FlowJo 
The MFI for the positive cell population was found and divided by the negative population. The 
higher this ratio was the higher separation of the two cell populations.  
  Figure 4.1 A, B and C shows how the separation of the positively stained cells from the 
negative ones varied, as the concentration got lower. For the cytokine titrations, PMA/IC were 
used to stimulate the PBMCs, as this antigen has shown to be able to elicit production of all the 
cytokines investigated in this project. The titrations for the markers CD3, CD4, CD8, CD14 and 
LIVE/DEAD were done using unstimulated fresh PBMCs. The late activation and memory 
markers, CD25, CD26, HLA-DR and CD45RO were titrated after six days of stimulation with 
SEB. CellTrace labeling results are given in section 4.1.4.  All of the cells used in the titrations 
were from healthy volunteers.  
  The titrations were done for all the antibodies before combinations of different 









Figure 4.1 A Titration of the fluorochrome-conjugated antibodies and dyes used in this project.  
From upper right: titration of CD3, titration of CD4, titration of CD14, titration of LIVE/DEAD, titration of CD26 
and titration of CD8. The x-axis represents the concentration of FAB used per 100 µL staining medium. The y-












Figure 4.1 B: Continuation of the titration of the fluorochrome-conjugated antibodies and dyes used in this 
project. From top right: Titration of CD25, titration of CD197, titration of CD45RO, titration of HLA-DR, titration 
of IFN-γ and titration of CD45RA. The x-axis represents the concentration of FABused per 100 µL staining 
medium (per 1000 µL for LIVE/DEAD). The y-axis represents the mean fluorescence intensity (MFI) of the 









Figure 4.1 C: Continuation of the titration of the fluorochrome-conjugated antibodies and dyes used in this 
project. 
From top right: Titration of TNF-α, titration of IL17A, titration of IL-4 and titration of IL-10. The x-axis represents 
the concentration of FAB used per 100 µL staining medium. The y-axis represents the mean fluorescence intensity 
(MFI) of the positive stained cell divided by the MFI of the negative cells. 
 
4.1.1.2 Final voltages used in the project 
Voltages of the different channels were adjusted in order to reduce spectral overlapping. A high 
voltage in one channel can contribute to “bleeding” into another channel. The voltage is also 
important for the separation of positively stained cell from the negative ones, as the negative 
stained cells should have low intensities and center between 0 and 1000 in a flow cytometric 
plot. The optimal voltages used in this project for the day one and the day six assays can be 
seen in Table 4.1 and Table 4.2. The voltages were found during the compensation and titrations 
of all the fluorochromes used in the project.  






Table 4.1: Voltages used on the flow cytometer and parameters for the day one assay  
Following parameters/channels were used in the day one setup characterizing intracellular cytokine profiles of 














450 ± 25 BV421-A – TNF-α 300 
525 ± 25 BV510-A – CD45RA 410 
605 ± 6 BV605-A – IL-17A 400 
710 ± 20 BV711-A – CD8 420 
Blue (488) 
530 ± 15 FITC-A – IFN-γ 410 
695 ± 20 PerCP-Cy5.5-A – CD4 490 
Yellow Green (561) 
582 ± 7.5 PE-A – IL-10 450 
610 ± 10 PE CF594-A – CD197/CCR7 460 
Red (635) 
670 ± 7 APC-A – IL-4 510 
730 ± 22.5 Alexa Fluor 700-A – CD3 440 
780 ± 30 
APC-H7-A – CD14/ 
LIVE/DEAD 
460 
*APC-H7 was used as a “Dump-channel”.  
 
 
Table 4.2: Voltages used on the flow cytometer and parameters for the day six assay  
Following parameters were used in the setup for the late activation, memory, proliferation and lineage markers on 











450 ± 25 Pacific Blue  –  CellTrace 300 
605 ± 6 BV605-A – CD45RO 400 
710 ± 20 BV711-A – CD8 420 




695 ± 20 PerCP-Cy5.5-A – CD4 490 
Yellow green (561) 582 ± 7.5 PE-A – CD26 450 
Red (635) 
670 ± 7 APC-A – CD25 510 
730 ± 22.5 Alexa Fluor 700-A – CD3 440 
780 ± 30 
APC-H7-A – CD14/  
LIVE/DEAD* 
460 
*APC-H7 was used as a “Dump-channel”.  
 
The voltages seen in Table 4.1 and 4.2 were adjusted and optimized according to one another. 
Voltages should be high enough to ensure that the unstained cells can be found around zero in 
a flow cytometric plot, while not too high for the positively stained cells to avoid spectral 
overlap. The compensation matrices for day one and day six assay were used as guidance during 
the development of the method. If the percentage of spectral overlaps were high (over 40 %) in 
the compensation matrix, the voltages were adjusted. Antibodies conjugated to APC-H7 were 
defined as a “dump channel”, so that dead cells and monocytes stained with  
APC-H7, could be excluded from the analysis.  
 
4.1.1.3 Compensation matrices  
Compensation was done by using Compensation Particle set beads (Mouse or Rat IgG, 
depending on the isotype for a specific antibody) for all of the FABs or dyes, except for 
CellTrace. Live and fresh cells had to be used for obtaining a relevant fluorescence intensity 
signal for CellTrace on the flow cytometer. The compensation matrices for the project can be 





Figure 4.2: The compensation matrices for day one and day six assay  
Day one assay compensation matrix shows the percentage of leakage into other channels; the spectral overlap.  
Day six assay compensation matrix shows the corresponding spectral overlap.  
 
The compensation matrices represent how spectral overlap manifested in this project.  More 
staining antibodies/dyes were used in the day one assay, and higher spectral overlaps can be 
seen here. Spectral overlaps should not exceed 50 %, and even if there is more spectral overlap 
from the day one matrix, none of them exceeds 40%.  The lineage markers were deliberately 
put on markers with a high degree of spectral overlap. Usually a distinct cell population was 
possible to discern for these markers. Bright fluorochromes with less overlap were preferred 
for the cytokine antibodies. 
 
4.1.2 Fixation and permeabilization; comparison of Cytoperm/cytofix vs. 
Formaldehyde, Triton X-100 and methanol 
Many different reagents can be used for fixation and permeabilization of cells. The order of the 
staining and the chemicals can influence the result obtained in such a method. 
Two different protocols with two different staining sequences were compared in order to gather 
information on how the cytokines would be stained, by the fixation and/or permeabilization. 
CD8+ cells and their expression of cytokines were tested in these protocols. CD4+ cells could 




two protocols.  Rearrangement of antibody clones and panel was done later on.  
  The first method consisted of using cytoperm/cytofix kit, while the other one was an 
alternative method where formaldehyde, Triton X-100 and methanol were used. All the PBMCs 
were stimulated for 4 hours with PMA and IC and the cytokine secretion inhibitor agent 
Brefeldin A was added at the same time.  
The staining order was done by either staining the cells in two steps or one step. When the cells 
were stained in two steps, surface markers FABs was added to the cells. Next the cells were 
fixated and permeabilized, followed by intracellular staining. For the one-step staining order 
the cells were fixated and permeabilized followed by surface- and intracellular staining 
simultaneously. The percentages of cytokines can be seen in Table 4.3.  
 
Table 4.3: Comparison of percentage of Lymphocytes and cytokines in CD8+ cells by using cytoperm/fix kit 





















1 step 54066 2.83 1.34 0.097 0.29 0.019 
2 steps 22565 1.97 1.06 0.024 0.97 0.018 
Formaldehyde, 
Triton X-100  and 
methanol 
1 step 4636 0.47 8.75 0.12 0.25 0.02 
2 steps 
13292 5.26 9.09 0.14 0.51 0.13 
  
As can be seen by Table 4.3, the number of CD8+ T cells differed for the two methods. This 
could be due to cell loss when washing and re-suspending and the different reagents used. 
  The percentage of IFN-γ, using cytoperm/cytofix, was increased when the staining was 
done in one step, while fewer cells got stained if two separate steps were used. The opposite 
seemed to be the case when using formaldehyde, Triton X-100 and methanol, where more IFN-
γ got stained when doing the staining in two steps For this cytokine both a two step and a one 
step staining order could be use, depending on which reagents were used for the fixation and 
permeabilization.  
  TNF-α+ cells found using the two different methods seemed to vary a lot. One staining 




separating the staining into two steps. Using the Formaldehyde, Triton X-100 and methanol on 
the other hand, gave significantly higher percentages of TNF-α+ cells and two staining steps 
gave most positive cells.  
  For IL-10, a smaller quantity of cells got stained when using the cytoperm/cytofix  
compared to the formaldehyde, Triton X-100 and methanol protocol.  A two step staining order 
using this protocol gave more positive cells. 
  For IL-17A both of the different methods gave best results when the staining order was 
divided in two. The cytoperm/cytofix protocol however, gave more IL-17A+ cells than the 
formaldehyde, Triton X-100 and methanol protocol.   
  The formaldehyde, Triton X-100 and methanol method resulted in more IL-4+ cells than 
cytofix/cytoperm, and was best noticed when the staining was done in two steps.  
  For most of the cytokines the formaldehyde, Triton X-100 and methanol protocol done 
in two staining steps seemed to be better. For IL-17A on the other hand, the best protocol was 



















Figure 4.3 represents flow cytometric plots of the CD4+ vs. CD8+ cells and the CD3+ cells vs. 
the dump channel. The CD4 antibody was in this experiment coupled to the fluorochrome 
 
 
Figure 4.3: T-cell populations using 
Cytoperm/cytofix or Formaldehyde 
Triton X-100 and methanol fixation and 
permabilizaton protcols.  This figure 
shows stimulated and stained PBMC.
  
A:The x-axis represents CD8+ cells and the 
y-axis represents CD4+ cells.  
B: The x-axis represents the Dump-channel 
with dead and CD14+ cells and the y-axis 




Brilliant™ Violet 510 and had the clone OKT4 (Biolegend), while the final one was coupled to 
PerCP-Cy5.5 and expressed the clone L200 (BD Biosciences). The clone tested in this 
experiment was not compatible with intracellular staining, as the fixation and/or 
permeabilization made it impossible to separate the CD4+ cells from the negative ones.  
  The CD3 antibody used in this experiment was coupled to the fluorochrome Alexa Fluor 
700. The same antibody and fluorochrome has been used in the final panel, but the CD3 used 
in this experiment expressed the clone HIT3a (Bio legend), while the final one expressed 
UCHT1 (Bio legend). The CD3 antibody clone tested in this experiment did not show 
compatibility with the cytofix/cytoperm, as the CD3+ cells could not be separated from CD3- 
cells. The CD8 used in this panel was coupled to FITC and had the clone aRPA (Bio legend). 
  The panel for which these two protocols were tested did have a compensation matrix 
where some of the spectral overlap was over 80 %.  This panel was changed in order to avoid 
spectral overlap, but also due to the importance of having dim markers on bright and medium 
fluorochromes and use dim fluorochromes on markers that are highly expressed (such as surface 
markers). The lineage markers used in the final panel were put on fluorochromes with higher 
spectral overlap, and not placing fluorochromes targeting cytokines on these fluorochromes. 
 
4.1.3 Exploring markers for CD8+ cells 
To assess the importance of CD8+ cells in immune responses against Giardia, another panel of 
FABs were tested. The CD8 cell toxicity was investigated by using the early T cell activation 
marker, CD69 on day one and perforin. On day six CD107a, a marker for degranulation in CD8+ 
cells was investigated. The fluorochrome panels were initially developed to investigate both 
CD4 and CD8 responses, but could not assess effector memory CD4+ T cells on day one. The 
FAB CD197 was included in the day six assay panel to assess its expression in activated and 
proliferating cells. The information about the FABs tested and the day one and day six panels 
are included in Appendix D.  
  During the method development, perforin positive cells percentages were similar for 
both unstimulated and stimulated cells. As a result no specific responses were found for this 
protein linked to cytotoxicity on CD8+ cells. The staining had to be done during the last 6 hours 
of stimulation in the medium. Due to the above considerations, the staining with CD107a was 
not done. The effector memory CD4+ T cells were thought to be a better approach in order to 
analyze specific immunity. CD69 was therefore excluded from the day one panel and replaced 




panel. In this way we could identify the memory effector CD4+ T cell populations, and exclude 
the naïve and central memory T cell populations.  
 
4.1.4 CellTrace failures and triumphs  
4.1.4.1 Uneven labeling of CellTrace 
CellTrace is useful for monitoring proliferation of cells during stimulation with antigens. When 
labeling with CellTrace, it is important to include a good positive control,that labeling 
concentration is optimal for viability of cells and for separation of generations, and that the cells 
are evenly labeled initially.   
  A problem seen when labeling cells with CellTrace, was that the unstimulated cells 
could appear to be proliferating, and this was not expected for a negative control (Figure 4.4). 
Even labeling, giving a bright peak and good separation of the positive cells from the negative 
cells is essential for monitoring proliferation.  
A new labeling protocol was therefore of high priority to develop.  
 
 
Figure 4.4 Overlayed histograms of an unstimulated unstained cell population (pink) and unstimulated 
CellTrace labeled cells (blue) collected after 3 days in culture.  
Uneven staining of the unstimulated cells falsely showing cell division, and weakly positive cells gradually down 
to the level of unlabeled cells. 
4.1.4.2 Labeling media for CellTrace 
To fix uneven labeling, different staining solutions were tested. The two different staining 
solutions tested for CellTrace was PBS and Medium. Following the manufacturer’s protocol, 
staining should only be done in protein-free media such as PBS, because CellTrace could bind 




Labeling of the cells with CellTrace was done on day 0, when the cells were harvested. Next 
the cells were counted, and suspended in medium. It would seem bothersome and unfavorable 
to wash the cells out of the X-vivo medium, stain in PBS, wash and re-suspend in X-vivo 
medium again. An alternative labeling would be ideal in order to save time, and use less X-vivo 
medium. Figure 4.5 shows how the staining results were when labeled in medium and in PBS. 
 
 
Figure 4.5: Histograms of CD3+ cells stained with 20 mmol/mL CellTrace for 10 minutes in medium or in 
PBS.  
The x-axis represents the intensities of CellTrace in the wavelength channel and the y-axis represents cell count. 
 
This demonstrates a more even and bright labeling of cells when stained with CellTrace in 
medium compared to staining in PBS. Medium was chosen as the best staining media in this 
project, and the voltage and CellTrace labeling consentration was adjusted to a peak intensity 
distributed evenly around 105, and provided good separation of the stained cells from the 
negative ones. Staining in PBS gave a peak intensity so bright that it cannot be seen in the plot. 
The optimal voltage for the negative population (not shown in figure) was used during the 
testing of CellTrace. The voltage used in this experiment placed the unstained cell population 
evenly around zero and showed to not be compatible with CellTrace labeling in PBS. Both of 
the cell samples used in the test was stained with CD3 in order to test the performance of 
labeling specifically for T cells. 
4.1.4.3 Positive proliferation controls 
 Different antigens were tested to show their corresponding proliferation. PPD was a good 
candidate as a positive protein control, because this antigen could provide a clean antigen- 
specific response, and study participants were all previously immunized with the BCG-vaccine 
against Mycobacterium tuberculosis. Figure 4.6 shows how some of the tested antigens 





Figure 4.6: Histograms of various candidates for positive controls for CellTrace after 6 days of stimulation. 
The x-axis represents the intensities of CellTrace in the wavelength channel and the y-axis represents cell count. 
A) Unstimulated cells, B) PPD, where a small peak can be seen towards left in the plot. C) Next LPS stimulated 
cells are shown where 5 generations of the cells can be spotted. D) SEB stimulated cells are shown in the next plot 
where 5 generations of cells can be spotted.  
 
In addition to using PPD as a positive control, SEB was also seen as a good candidate for 
proliferation responses. The reason for this was that SEB gave a high percentage of proliferating 
cells, where many cell generations could be seen (Figure 4.6). The individual responses to PPD 
could vary and sometimes be weak, and SEB would therefore provide information regarding 
cell proliferation. LPS could have been included as a positive control as well, but SEB was 
chosen due to stronger proliferative responses.  
 
4.1.4.4. Concentration of CellTrace  
The concentration of CellTrace is important for distinguishing between positively stained and 
negative cells. According to manufacturer’s protocol, the concentration of CellTrace should be 
5 mmol/mL in order for it to carry out its function as proliferation marker. The incubation time 
should in addition be 20 minutes in a CO2 incubator followed by repeated washing steps.  
  In this project the staining medium was changed, and as a result of this, the concentration 




mmol/mL in addition to using an incubation period of 10 minutes at room temperature. This 
provided even labeling and gave a bright stained population, which could be separated from the 
negative cells at the optimal voltage. 
  The peak for CellTrace labeled unstimulated cells was uneven and it appeared to be 
proliferating (Figure 4.4), and looked like this before the optimized staining protocol done in 
medium was established. Figure 4.5 demonstrates even labeling when changing the staining 
media. 
Labeling in PBS could be a contributor to the wide peak seen for the unstimulated stained cells 
in Figure 4.4.    
 4.1.5 Prevention of cell loss 
A problem that was experienced during the entire method developing period, was cell loss. A 
good analysis of antigen-specific cytokine producing T cells cannot be done with very few cells, 
as these are rare events. Preparation of cells for flow cytometric analysis is a lengthy process 
involving many washing, staining and analysis steps where cells are lost. Optimizing of the 
procedures to avoid cell loss was therefore given high priority. 96 U-wells plates were at first 
used for the entire protocol for flow cytometric analysis. The problem with these plates was 
that it is easy to disturb the cell pellet when removing supernatants and re-suspending cells. 
Switching to using 96 V-wells plates made it easier to avoid disturbing the cell pellet. However, 
it rarely resulted in more than 1/10 of the starting cell population being available for analysis. 
  Removing supernatants and re-suspension of cells were critical steps in order to avoid 
cell loss. Making the pellet more firm makes it easier to discard cells when removing 
supernatant.   The centrifuge speed used for plates was originally 400 RCF. The RCF was 
adjusted up to 450 for all steps, except after the fixation and permeabilization, where the RCF 
was increased further up to 600 RCF. These settings on the centrifuge generally yielded more 
cells available for analysis. The higher RCF on the centrifuge made it possible to flick the 
supernatants into a biohazard trash, instead of pipetting. Cells can adhere to the tips of pipettes, 
and some volume seemed to be left in the tips after re-suspension. By flicking the plate, more 
cells could be obtained for the flow cytometric analysis.  
  Another crucial step to make sure that the cell loss was kept to a minimum was using a 
plate reader instead of flow tubes on the flow cytometer. This avoided cell loss in the 96 V-
wells plate and remnants in the pipettes.  Using the plate reader also saved a lot of time.  
  The fixation and permeabilization done before intracellular staining was a contributor 




methanol method. Generally 16 % of cells were available for analysis when using cytofix-
/cytoperm, and only 2 % of cells were generally available when using formaldehyde, Triton X-
100 and methanol (Table 4.3 shows available cells for analysis using this protocol). 
Cytofix/cytoperm was therefore chosen to be used prior to intracellular staining in this project, 
as the number of cells for analysis was of high priority.  
    
 4.1.6 Quality control of cell gating 
 When analyzing data obtained by flow cytometry, populations of cells of interest were gated 
and investigated further. Gating of a population can be especially difficult if the two populations 
with negative and positive cells overlap due to continuous expression of the specific marker of 
interest. Cytokines can be produced in small amounts, and the gate threshold is of crucial 
importance, as it can heavily influence the percentage of cytokine producing cells.   
  Fluorescence minus one (FMOs) controls were included in the piloting of exposed and 
unexposed persons, and for every participant in the comparative experiment conducted. The 
FMOs showed how background and spectral overlap would be in a specific channel, when that 
FAB is missing. Figure 4.7 and Figure 4.8 shows how the FMOs looked like for the day one 
and day six assays. In addition to FMOs, an unstimulated stained cell sample (medium only) 
was always included for every participant in the two groups. These cells showed how the 
background production of cytokines would be, so that this background could be subtracted for 
each participant. It was also a helpful tool to set gating. To control for autofluorescence, an 
unstained sample of cells for all the antigens used was included.  These cells could show how 






Figure 4.7: Fluorescence minus one (FMOs) controls stimulated for 24 hours with PMA/IC in day one assay. 
A) IL-4 FMO, B) IL-17A FMO, C) TNF-α FMO, D) IFN-γ FMO and E) IL-10 FMO. The gates set here were used 

















Figure 4.8: Fluorescence minus one (FMOs) controls stimulated for 6 days with SEB in day six assay. 
A) CD45RO FMO, B) CD25 FMO, C) HLA-DR FMO and D) CD26 FMO. The gates set here were used as the 
standard gating for the day six assay.  
 
The FMOs (Figure 4.7 and 4.8) show that background staining and spectral overlap will not 
contribute to false positives to a certain extent.  
 
4.2 The pilot study of Giardia-specific T cell responses 
4.2.1 Participants  
In total, fifteen Giardia exposed persons and ten low risk healthy controls were included in the 
study. In the Giardia exposed group 13.3 % (N=2) were unexpectedly still Giardia positive. 
We found generally stronger responses in these two individuals than in the rest of the Giardia 
exposed group, and therefore they were analyzed separately. The correlation of responses 
between SSA and SSB include all the participants from both groups. Characteristics for the 
















P-values for all the CD4+ T cell responses, when stimulated with SSA and SSB. compared 
between the two groups measured in SSA and SSB is attached in Appendix E. 
  








Individuals in each group (n) 2 13 10 - 
Female gender, n (%) 1 (50.0) 8 (61.0) 7 (70.0) 1.0 
Age (years), mean (SD) 39.5 (23.3) 42.5 (18.3) 46.8 (17.0) 0.57 
Infection duration, weeks (range) 8.5 (5-12) 10.3 (1-54) NA 0.48 
Mean time since giardiasis to 
sampling, weeks (range) 
NA 51.5 (1-112) NA NA 
There were no significant baseline differences between the groups (Fisher’s exact test for categorical, non-
parametric Kruskal-Wallis test for continuous variables).   
NA: not applicable.  
  
4.4.2 Day one findings  
4.4.2.1 Lymphocytes and CD4+ cells 
The average number of lymphocytes analyzed in this project was important. A larger number 
of lymphocytes analyzed, would give a more accurate estimation of rare cell events. Table 4.5 
shows the average number of lymphocytes and CD4+ cells found for all individuals in the 
Giardia exposed group (Ag) and the all the low risk healthy control group (LR).  
 
Table 4.5: Average number of lymphocytes and CD4+ cells acquired in the day one assay.  
 Stimulation media LR Ag 
Lymphocytes  (n) 
MED 736100 661902 
SSA 431736 391069 
SSB 435447 393742 
PPD 405088 354742 
LPS 392635 312894 
PMA/IC 307202 249088 
Average All 451368 393906 
CD4
+
 T cells (n) 
MED 291145 281931 
SSA 179273 178380 




PPD 171069 158379 
LPS 156777 132200 
PMA/IC 103134 94358 
Average All 180613 170359 
 
 
4.4.2.2 Flow cytometric plot of IL-17A producing cells  
The cytokine responses were compared between the study groups. We explored cytokine 
producing cells both in the whole CD4+ T cell population and in the smaller CD4+CD197-
CD45RA- effector memory T cell population. We found antigen activated cytokine producing 
cells to be concentrated if the effector memory population (Figure 4.9). We concentrated the 




Figure 4.9: IL-17A+ expressing CD4+ T cells in a CD197-CD45RA- plot  
IL-17A+ cells are represented by black dots in a gray CD4+ T cell population. Cell plots represent one participant 
from the recent giardiasis group (Ag) and one participant from the low risk healthy control group (LR). The flow 
cytometric plots represent cells in medium only (MED), and cells stimulated with SSA, SSB or PMA/IC. The IL-






4.4.2.3 Percentages of cytokines expressed by effector memory CD4+ cells  
The cells were gated according to the strategy shown in Methods. Analysis of cytokines 
producing antigen-specific effector memory CD4+CD197-CD45RA- T cells, was the main focus 
for the day one assay. The assay allowed analysis of TNF-α, IFN-γ, IL-17A, IL-4 and IL-10 
secreting cells after 24 hours antigen stimulation. We also analyzed multifunctional cells able 
to produce both TNF-α and IFN-γ. Data from FlowJo was used to make bar charts in SPSS of 
responses seen in each study group. In the recent giardiasis and low risk control group, the mean 
percentages of theses cytokine producing cells, with bars showing the 95 % confidence interval 
(CI), can be seen in Figures 4.10-4.14. Because there were only two participants in the current 
giardiasis group, these are represented by their measured values, rather than a mean value and 
95 % CI bars. Correlation of IL-17A responses in SSA and SSB stimulated effector memory 
CD4+ T cells is presented in Figure 4.15.  
 
 
Figure 4.10: Cytokines produced in the effector memory CD4+ T cell subsets when stimulated with SSA. 
Average percentage expression of cytokines in the effector memory CD4+ T cells are represented by the y-axis 






Figure 4.11: Cytokines produced in the effector memory CD4+ T cell subsets when stimulated with SSB. 
Average percentage expression of cytokines in the effector memory CD4+ T cells are represented by the y-axis 
and the various cytokines measures are presented on the x-axis.  
  
 
Figure 4.12: Cytokines produced in the effector memory CD4+ T cell subsets when stimulated with PPD. 
Average percentage expression of cytokines in the effector memory CD4+ T cells are represented by the y-axis 





Figure 4.13: Cytokines produced in the effector memory CD4+ T cell subsets when stimulated with LPS. 
Average percentage expression of cytokines in the effector memory CD4+ T cells are represented by the y-axis 
and the various cytokines measures are presented on the x-axis.  
  
 
Figure 4.14: Cytokines produced in the effector memory CD4+ T cell subsets when stimulated with PMA/IC. 
Average percentage expression of cytokines in the effector memory CD4+ T cells are represented by the y-axis 






Figure 4.15: Scatter plot of the correlation of IL-17A responses in SSA and SSB stimulated effector memory 
CD4+ T cells.  
The x-axis represents SSA stimulated percentages of IL-17A+ effector memory CD4+ T cells and the y-axis 
represents SSB stimulated percentages of IL-17A+ effector memory CD4+ T cells.  
    
Data for the two participants found to have current giardiasis were not statistically compared to 
the other two groups. However, we qualitatively evaluated their responses compared to the 
other groups.   
   The cytokine IL-17A was statistically more expressed in effector memory CD4+ T cells 
in the recent giardiasis group, compared to low risk controls, when stimulated with SSA 
(P=0.035) but not with SSB (p=0.062). For comparison we also compared cytokine producing 
cells in the general CD4+ T cell population and found P=0.043 for SSA and P=0.037 for SSB. 
Figure 4.10 and 4.11 also demonstrated that the two individuals with current giardiasis have 
higher percentages of cells producing TNF-α, IFN-γ, doubly producing TNF-α and IFN-γ, and  
IL-17A in response to Giardia soluble proteins SSA and SSB.    
  Figure 4.15 represents correlation between IL-17A memory effector CD4+ T cell 
responses when the cells were stimulated with SSA and SSB. By linear regression analysis, we 
found a significant positive correlation between these two antigen solutions made from the two 
distinct isolates of Giardia. All the cytokines tested for correlation between SSA and SSB 




of goodness-of-fit, for the correlation of IL-17A responses between SSA and SSB was 0.941.  
The percentages of IL-4 and IL-10 positive cells were low in all of the tested stimulation media.   
      
4.4.3 Day six findings  
4.4.3.1 Lymphocytes and CD4+ cells 
The average number of lymphocytes found in the project was important. Surface markers 
analyzed for day six were not considered to be rare events such as cytokines. Fewer cells were 
therefore used in the day six assay. Table 4.6 shows the average number of lymphocytes and 
CD4+ cells found for the Ag group and the LR group.  
 
Table 4.6: Average number of lymphocytes and CD4+ cells acquired in the day six assay 
 Stimulation media LR Ag 
Lymphocytes (n) 
MED 60786 105385 
SSA 63370 60091 
SSB 63605 55432 
PPD 59344 63299 
SEB 86241 72434 
Average All 66669 71328 
CD4
+
 T cells (n) 
MED 60786 61932 
SSA 34800 32374 
SSB 35834 29460 
PPD 27633 31053 
SEB 34091 30212 
Average All 38629 37006 
 
 
4.4.3.2 Flow cytometric plots of activation markers and proliferation on day six 
The cells in this assay were gated according to the strategy shown in Methods. The surface 
activation responses and proliferation rates were compared between the study groups. We 
explored up-regulation of CD25+/CD26++, CD45RO+/HLA-DR+ and combination of 
CD25+/CD26++ and CD45RO+/HLA-DR+ CD4+ T cells and proliferation of CD4+ T cells. We 
found antigen activated CD45RO/HLA-DR (Figure 4.16) and quadruple positive cells for the 
surface markers (Figure 4.17) to be up-regulated in the analysis. Proliferation of CD4+ T cells 






Figure 4.16: HLA-DR+CD45RO+ in CD3+CD4+ T cells.  
Cell plots represent one participant from the recent giardiasis group (Ag) and one participant from the low risk 
healthy control group (LR). The flow cytometric plots represent cells in medium only (MED), and cells stimulated 
with SSA, SSB, PPD or SEB.  The x-axis represents CD45RO, and the y-axis represents HLA-DR. The square in 
each cell plot represent the gate used to look at the double positive cells.  
 
 
Figure 4.17:  Quadruple positive cells of CD25/CD26 and HLA-DR/CD45RO  
Cell plots represent one participant from the recent giardiasis group (Ag) and one participant from the low risk 
healthy control group (LR). A gray CD4+ T cell population is represented, and the x-axis represents SSC-A and 
the y-axis represents FSC-A. The black dots represent quadruple positive cells of CD25/CD26 and HLA-
DR/CD45RO. The flow cytometric plots represent cells in medium only (MED), and cells stimulated with SSA, 





Figure 4.18: Proliferating CD4+ T cells in the two groups  
Cell plots represent one participant from the recent giardiasis group (Ag) and one participant from the low risk 
healthy control group (LR). The x-axis represents CellTrace proliferation dye and the y-axis represents SSC-A. 
The flow cytometric plots represent proliferating cells in medium only (MED), and cells stimulated with SSA, 
SSB, PPD or SEB.  
 
Figure 4.16 represents HLA-DR and CD45RO positive cells found in the day six assay from an 
individual from the LR group and an individual from the Ag group.  The stimulation with SSA 
gave significant findings for the HLA-DR/CD45RO activation markers. The negative control, 
MED, gave no positive responses in neither of the participants. The SSA stimulated cells gave 
some weak responses in the LR individual and a strong response in the Ag individual. SSB 
stimulation have less positive cells in the LR individual, and in the Ag individual a positive cell 
population can be found in the HLA-DR/CD45RO gate. The positive cells found for the SSB 
stimulated cells can correspond to specific responses. The PPD and SEB, positive controls, gave 
responses in both of the individuals, but the cells from an individual in the Ag group seem to 
be more activated than the individual from the LR group. No differences of statistical 
significance were found for PPD stimulation between the groups.  
   Figure 4.17 demonstrates black quadruple positive cells of the four surface activation 
markers (CD25, CD26, CD45RO and HLA-DR) displayed in black in a grey CD4+ T cell 
population shown in gray.  
      
4.4.3.3 Percentages of activated and proliferating CD4+ T cells 
Analysis of surface activation markers and proliferation was the main focus for the day six 
assay. The percentages of CD4+ T cells showing activation and proliferation were compared 
between the Ag and the LR group. The assay allowed analysis of doubly positive CD25/CD26 




and proliferation after six days of antigen stimulation. Data from FlowJo was used to make bar 
charts in SPSS of responses seen in each study group. In the recent giardiasis and low risk 
control group, the mean percentages of the surface activation responses and proliferation are 
displayed with bars showing the 95 % CI (Figures 4.19-4.22). Because there were only two 
participants in the current giardiasis group, these are represented by their measured values, 
rather than a mean value and 95 % CI bars.  
 
   
 
Figure 4.19: Activation markers and proliferation of CD4+ T cells when stimulated with SSA.  
Average percentage expression of surface activation markers and proliferation of CD4+ T cells are represented by 





Figure 4.20: Activation markers and proliferation of CD4+ T cells when stimulated with SSB.  
Average percentage expression of surface activation markers and proliferation of CD4+ T cells are represented by 




Figure 4.21: Activation markers and proliferation of CD4+ T cells when stimulated with PPD.  
Average percentage expression of surface activation markers and proliferation of CD4+ T cells are represented by 






Figure 4.22: Activation markers and proliferation of CD4+ T cells when stimulated with SEB.  
Average percentage expression of surface activation markers and proliferation of CD4+ T cells are represented by 
the y-axis and the various markers and proliferation measures are presented on the x-axis.  
 
 
Figure 4.23: Linear regression analyses of correlation of proliferation percentages between SSA and SSB 
stimulated CD4+ T cells.  
The x-axis represents SSA stimulated percentages of proliferating CD4+ T cells and the y-axis represents SSB 
stimulated percentages of proliferating CD4+ T cells. Current giardiasis individuals are represented by red dots, 
recent giardiasis individuals are represented by pink dots and low risk controls are represented by green dots. 




  For the SSA stimulated cells, CD45RO and HLA-DR positive cells were found to be 
significantly up-regulated in the Ag group with a P-value of 0.036. Quadruple positive cells for 
CD25, CD26, CD45RO and HLA-DR did also differ between the groups giving a P-value of 
0.041. The CD25/CD26 alone did not show statistical significance, P=0.088. Figure 4.18 
demonstrates proliferating CD4+ T from the two groups. The proliferation did not show 
statistical differences between the two groups P=0.208  
   Figure 4.23 presents the correlation between proliferation of CD4+ T cells when the cells 
were stimulated with SSA and SSB. By linear regression analysis, we found a significant 
positive correlation with a P-value under 0.001, and an R2 value of 0.455. 








5.1 Methodology  
 
5.1.1 The voltages and compensation matrices 
The voltages and the optimal concentration of a fluorochrome is important for setting up 
compensation. When the voltage set up for one fluorochrome is adjusted, the corresponding 
relationship between detectors will change, and  the values of the compensation will change 
accordingly [77].   
  The voltages used in this study were based on repeated analysis and adjustments using 
single stained beads for flow cytometry, and also during titrations with live cells. It was not-
iced that the voltage values were important for how the spectral overlap manifested. A good 
compensation matrix should show as little spectral overlap as possible, but when multicolor 
fluorochrome panels are used, more spill over will be seen. By optimizing the voltages for the 
different channels, spectral overlap being 80 % and over, was adjusted to under 40 % by 
continued adjustment. Lineage makers being easy to separate from one another should therefore 
be placed on channels were spectral overlap is expected to manifest, whereas one should be 
careful with rare event populations such as cytokines.  
  Day-to-day variations in a flow cytometer can result in different results for a 
compensation matrix. A CST was done every day the flow cytometer was used, as a quality 
control for these variations. Considering day-to-day variations, compensation acquisition using 
single stained beads with FABs should be run prior to every flow cytometric experiment.  A 
new compensation matrix was not made for every new experiment in the present study. 
However, several compensation matrices were tested and one for the day one assay and one for 
the day six assay showed to be reasonably stable over time. Figure 4.2, which represent the 
compensation matrices in this study, may have manifested differently according to the day the 
compensation was run.  
 
5.1.2 The permeabilization and fixation reagents  
As demonstrated earlier, two separate protocols were tested for the fixation and 
permeabilization of the cells. Formaldehyde, Triton X-100 and methanol did show to be a 






compared to cytoperm/cytofix. The CD4 FAB clone tested in this experiment did not give good 
lineage separation, so CD8+ T cells were used to compare cytokine expression instead. We later 
settled to analyze only CD4+ T cells, and the cytokines produced by CD8+ T cells when testing 
fixation and permeabilization reagents, could be misleading. The testing of these reagents was 
also performed at an early stage in the study, before we started using FMOs and negative 
controls with unstimulated stained cells and unstained cells. Some caution was therefore  taken 
about the gating and measurements in this testing setup. Cell loss during the staining and 
permeabilization procedures was our major problem in the start. Cytoperm/cytofix gave a 
reasonable number of cells available for flow cytometric analysis, and these are the reagents 
most widely used in published method papers and intracellular T cell assays. In addition, the 
formaldehyde, Triton X-100 and methanol protocol takes 60 more minutes to conduct. The 
cytoperm/cytofix protocol was therefore chosen as the fixation and permeabilization reagent 
for further experiments.  
 
5.1.3 Validation of CellTrace assay  
Measurement of proliferation of antigen-specific cells can give a good indication of memory 
immune responses [65]. Cell division can be tracked using different methods, both flow 
cytometric and by nucleoside uptake of proliferating cells [65].  
 An earlier study investigating proliferation in response to SSA and SSB [10], used 3H-
thymidine assay to evaluate proliferation. The 3H-thymidine was in this study added to the 
PBMCs after 5 days of stimulation with SSA and SSB. 3H-thymidine incorporation in dividing 
cells could then be measured.  
  The flow cytometric assay for investigating proliferating cells is more specific than 
incorporation of 3H-thymidine. The reasons for this is that in addition to proliferation tracking, 
specific cells exhibiting phenotypic or functional characteristics can be gated and investigated 
further when using flow cytometry [78].  
  Flow cytometric dye dilution with CellTrace was chosen as the proliferation tracking 
agent in this study and to investigate the percentages of proliferation together with the surface 
activation markers. Being able to analyses the proliferating of CD4+ T cells to investigate 
Giardia-specific immune responses was one of the aims for this study. To avoid working with 
radioactive substances, and to be able to analyze the specificity of the proliferating subsets, 3H-
thymidine assay was not chosen in this study.  






would be recorded during the entire culturing period. Incorporation of 3H-thymidine, on the 
other hand, would just have investigated cells still proliferating after 5 days, since only these 
cells would take up 3H-thymidine. The proliferation ratio seen in a 3H-thymidine assay will be 
based on an entire population of mixed cells and proliferation of specific subsets cannot be 
assessed.  
  The proliferation of CD4+ T cells in this study was not significantly different between 
Giardia exposed and unexposed. A larger study population could perhaps have given more 
information regarding proliferation as the p-value for the SSB proliferation was close to 0.05. 
  Measuring proliferation with CellTrace investigation has its limitations. Using too high 
concentration of this dye can be toxic to cells and result in reduced proliferation. Cells that are 
activated without starting to proliferate will be missed. Also the lack of differential proliferation 
responses might be due to cross-reacting immunity, or unknown previous Giardia infection, in 
the low risk controls. No significant p-values seen for proliferation measurements does not 
necessarily mean that Giardia-specific immunity does not exist for CD4+ T cells [78].  
 
5.1.4 The number of cells per well for the two different assays 
The number of cells per well and if duplicates or triplicates were used, could be variable.  For 
some of the individuals recruited, lower numbers of PBMCs were obtained from the four CPT 
tubes of blood, which was drawn from each participant. The number of PBMCs needed for the 
day one assay was 21 million, where two triplicates were used for the negative control, and one 
triplicate per antigen/positive controls. In the day six assay 2 x 105 cells were added to all the 
wells. A typical set-up consisted of 3 million PBMCs in the day six assay in order to fill 
triplicates to the 96 V-wells plate. If fewer cells than the required 24 million cells were obtained, 
duplicates were set up instead, resulting in fewer cells in the final analysis. Still, the lowest 
number of cells obtained from SSA or SSB stimulation in the day one assay was 68104 and 
30818 in the day six assay. Keeping all participants in the analysis, and using a cell 
concentration as close to 1 x 106 as possible for day one, where rare events were investigated, 
was considered to be important The standard cell concentration per well in the day one assay 
was 1 x 106 per well, and always higher than 6 x 105.   
  The differences in the cell concentrations used for the day one and day six assays were 
different due to the expected cell loss in the day one assay caused by the fixation and 
permeabilization steps and more washing steps. Additionally, cytokine producing cells are rare 






  Figures 4.10-4.14 demonstrates the percentages of cytokine producing cells obtained in 
this study. The percentages of cells producing IL-4 and IL-10 are generally lower than the 
percentages of the other cytokines. Percentages of IL-4+ effector memory CD4+ T cells for the 
stimulation media SSA and SSB were generally between 0.00-0.02 and too few cells were 
collected (Table 4.5) to give a CV of 5 %. Percentages of IL-4+ cells in the positive control 
PMA/IC, was however over 2 % and a CV over 5 % can be found. IL-4+ cell percentages can 
thus be unreliable and only gave a CV of 5 % in the PMA/IC positive control.    
  Percentages of IL-10+ cells were generally below 0.01 % for the stimulation media SSA 
and SSB not giving a CV of 5 %, while stimulation with PMA/IC gave 0.4 % IL-10+ cell or 
more. The average number of CD4+ T cells stimulated with PMA/IC were 103134 for the LR 
group and 94358 for the Ag group (Table 4.5). 100.000 total events should have been collected 
to give a CV of 5% for IL-10. The IL-10+ result detected in this study can therefore be 
unreliable.  
  An evaluation of how many cells are needed for analyzing the cells of interest should 
be done before a flow cytometric experiment is done, to avoid too few cells in the final sample. 
  Surface markers were investigated on day six, and these are more abundant and therefore 
more easily stained than cytokines. Because of fewer washing steps, cell loss was less of a 
problem. The responses being analyzed were also expected to be amplified through the 
proliferation of responding cells, thus positive events are not that rare. The percentages for 
responses found for the day six assays were generally over 1 %, meaning that at least 40 000 
cells had to be acquired to get a CV of 5 %. The average number of CD4+ T cells acquired in 
the day six assay in this study (Table 4.6) was 38629 for the LR group and 37006 for the Ag 
group. The numbers obtained for CD4+ T cells in this study are very close to 40 000. If a CV 
of 6 % was accepted for the day six assay, 27777 CD4+ T cells had to be aquired.   
  2 x 105 PBMCs were added to each well in this assay, and if a higher concentration had 
been used in the 96-well plates, the 200 µL medium could have been spent by growing cells 
before the sixth day was reached. This could have led to cell death or inhibition of proliferation 
and activation. For these reasons, a smaller T cell population was deemed adequate for 







5.1.5 Pitfalls in flow cytometry  
Several factor can influence the quality of a flow cytometric analysis and have to be taken into 
consideration. 
The importance of having a good compensation matrix with minimal spillover has been 
discussed earlier. Even if the compensation matrix is good, spectral overlap may still happen. 
The calculated compensations in the software program can be misleading. The fluorescence 
and scattered light recorded by the flow cytometer may change due to day-to-day variations in 
the laser [79].  The CST is therefore needed and important to do before analysis, to be aware of 
changes and failures in the flow cytometer.  
  Cell loss was seen during the development of the flow cytometric method. Having 
enough cells in the wells to compensate for cell loss during staining and permeabilization was 
important.  
  The acquisition of data during flow cytometry can be challenging. If an accessary plate 
reader for a flow cytometer is used, the wells have to be filled with a volume compatible with 
the flow cytometer, to avoid air in the machinery. Air can disturb the analysis, resulting in no 
valid data for the analysis.   
  Fresh cell samples were always used in this study, to avoid freezing and thawing of 
cells, leading to more cell death [61].  Dead cells should always be excluded from the 
analysis to avoid false positive non-specific binding by dead or dying cells [64].  
  The clones for a specific FAB is important for the affinity of a target [61] and as 
experienced in this study, the clones can also be incompatible with fixation and 
permeabilization reagents. The FABs and their antibodies should therefore be tested for such 
incompatibility. 
  Due to FABs capacity to be excited they are sensitive to light [61] and caution should 
be taken when staining cells, washing and analyzing to avoid degradation.   
  Some fluorochromes such as phycobiloproteins (APC and PE) have large molecular 
sizes compared to other FABs, and steric hindrance should be considered for the analysis of 
intracellular cytokines [61]. The IL-10 and IL-4 used in this study were coupled to, respectively, 
PE and APC, and low percentages of these cytokine producing cells obtained, can thus be 
speculated to be a result of both inadequate positive controls and steric hindrance. Still APC 
and PE are bright fluorochromes [61], and are often used for intracellular targets in flow 






rare events.  
 
5.2 Quality control  
When testing with flow cytometry, is essential to include positive and negative controls, as 
internal quality controls. Cytokine producing cells are as mentioned rare events, and in order to 
be able to investigate Giardia-specific CD4+ T cells, a negative control without cytokine 
producing cells is needed, as well as a positive control expected to give many positive events. 
These two internal controls can validate the status of the cells. If responses are seen in the 
negative control, contamination can have happened, and the results cannot be trusted. On the 
other hand, no responses for a positive control may indicate that the cells are not responding 
well to stimulation and the results may be weak for the tested antigens as well.   
  Figure  4.14 shows the percentages of the cytokine producing cells when stimulated with 
PMA and IC in this study. Large confidence intervals for the percentages are presents for all of 
the cytokines, and one individual with current giardiasis had weak responses overall. The other 
individual with current giardiasis has high responses for all of the respective cytokines 
compared to the other one. The unexpectedly low reaction to PMA/IC should raise caution that 
perhaps the PBMC of this participant were responding weakly to all of the antigens tested. 
Another reason could be that the weak response was due to the dilution of PMA and IC and the 
storage. New solutions were not made for every experiment, and the solutions may have lost 
some reactivity during storage. A standard procedure should have been used in this study for 
the PMA/IC positive control, by either using fresh made solutions for every new experiment, 
or using one-week-old solutions for every experiment. However, PPD and LPS were also 
included as positive controls in this study, and the individuals with current giardiasis shows 
responses in the expected range towards both PPD and LPS, and we concluded that the weak 
PMA/IC response was due to variations in its reactivity. Thus, the results seen for SSA and SSB 
could be trusted.  
  All of the 96 V-wells plates with antigens and negative control were made the same day 
and kept at -20 °C to keep day-to-day variations to a minimum. PMA and IC were added after 
18 hours of PBMC stimulation and therefore, and these reagents could not have been added to 
the 96 V-wells plate and kept frozen to avoid variations.  
  FMOs were used to set gates for the day one and day six assays. The FMOs were 






HLA-DR with where no definite separation of positively and negatively stained cells could be 
seen (Figure 4.8 and Figure 4.16).  
5.3 Evaluation of the immune responses   
5.3.1 Why use flow cytometry to look at immune responses?  
Flow cytometry has the advantage of recording multiple cellular markers at the same time.  
Cellular responses can be investigated according to surface markers or other phenotypic 
markers expressed on cells. Flow cytometry is unique in this respect compared to i.e. ELISA, 
where specific cell cannot be sorted and multipotent cells cannot be distinguished from other 
cells [78]. More specific responses can therefore be examined using flow cytometry [61]. 
5.3.2 Stimulation times  
The PBMCs were stimulated for a total of 24 hours in the day one assay. The duration of 
stimulation is essential, as different cytokines can have their highest levels of expression at 
different time points.   
  The cytokine IL-17 has showed to reach its peak level after 24 hours when stimulated 
with several reagents, including PMA and IC. Levels of IFN-γ and TNF-α were showed to be 
persistent after more than 24 hours for activated cells [80].   
  IL-10 producing cells have been examined in an earlier study [81], looking for the 
dominant cytokine responses in malaria exposed children. The PBMCs were stimulated for 24 
hours, and it is known that a stimulation time of 24 hours is needed to elicit IL-10 responses 
[63]. TNF-α and IFN-γ were also investigated in the malaria study and supports the stimulation 
time we used.  
  Due to IL-17A, IL-10, TNF-α and IFN-γ having been found after 24 hours of stimulation 
before, we decided use the same stimulation time. The duration of stimulation can affect the 
cytokine production, and optimally different stimulation periods could have been tested in this 
study.  Surface activation markers and proliferation in response to SSA and SSB have been 
investigated before, and suggested good responses after six days of culturing [10]. The same 
stimulation period was therefore chosen in the present study.    
 
5.3.2 CD4+ T cell responses against Giardia 
An effector response mediated by T cells have earlier been seen in mice studies. This indicates 
that control and eradication of an infection may be facilitated through an antibody-independent 






  The general CD4+ T cell production of IL-17A seemed to be a better approach to 
investigate Giardia-specific CD4+ T cell responses, as statistical significant differences 
between the recent giardiasis group and the low risk control group were found for both SSA 
and SSB. IL-17A+ cells were only found to be statistical significant in the CD4+ effector 
memory T cells when stimulated with SSA.  
  In cattle with current, on-going Giardia infection, IL-17A has recently been found to be 
up-regulated in proliferating PBMCs when stimulated with Giardia trophozoites [53]. FoxP3 
was also investigated in this study, which measured responses using qPCR. The IL-17A 
responses found in this cattle study suggest that Th17 responses may play a role in the protection 
and eradication of Giardia. Still, a larger human study population, preferably with current 
infection, is needed to validate our findings.  
  The surface activation markers HLA-DR, CD45RO, CD25 and CD26 on CD4+ T cells 
in addition to proliferation using a 3H-thymidine assay have been studied in individuals 5 years 
after initial Giardia infection [10]. Up-regulation of the surface markers were found in this 
study and the proliferation was also up-regulated. The expression of HLA-DR and CD45RO 
correlates with our findings and might suggest that up-regulation of these surface markers are 
specific for cellular immunity against Giardia.  Proliferation and CD25 CD26 did not, however, 
show to be statistically significant in our study. A larger study population exposed to Giardia 
should be used in order to assess proliferation and CD25 and CD26 up-regulation in  
  Correlation of IL-17A CD4+ effector memory T cell responses when stimulated with 
SSA and SSB, were found in our study. Also we found a positive correlation between SSA and 
SSB induced proliferation of CD4+ T cells. Immune responses have been shown to be 
assemblage independent before [10], and our findings support this.  
  Quadruple positive CD4+ T cells for all the surface markers, CD25, CD26, CD45RO 
and HLA-DR were significantly increased in the recent giardiasis group compared to the low 
risk control group in our study, when stimulated with SSA.  These findings suggest a Giardia-
specific immunity.  
5.3.2.1 Responses not seen in the project  
 
Up-regulation of some of the cytokines, that can be connected to a Th1 response, TNF-α and 
IFN-γ, were not statistically significant between the two groups, recent giardiasis and low risk 
controls. This result can be due to a small study population and small but unspecific responses 
in low risk healthy controls, large individual differences, undiagnosed previous Giardia in the 






however show up-regulation of TNF-α, IFN-γ and doubly positive cytokine producing TNA-α 
and IFN-γ. More individuals with current giardiasis are needed to investigate, if TNF-α and 
IFN-γ are up-regulated during infection.  
  It can be difficult to assess protective immunity from individuals who have had 
giardiasis. Reasons to this can be: protective immunity may only be partial, asymptomatic cases 
of infection is relatively common, variations between Giardia isolates expressing different 
immunogenic proteins can give differences and comparisons between studies can be limited 
due to different methods, antibodies, reagents and equipment [26].   
 
5.3.3 The status of the low risk healthy controls 
Some of the low risk healthy controls had small but unspecific responses against the Giardia 
soluble proteins we tested. Characteristics in the individuals, such as immune system, 
underlying ailments, earlier infection with other gut pathogens and/or Giardia assemblages  can 
be reasons for different responses between the three groups [10]. The CD4+ T cell responses 
seen for some of the low risk healthy controls can be due to several factors  
  Previous Giardia infection in low risk healthy controls can be difficult to assess, since 
a Giardia infection can pass unnoticed. The age of the low risk control would also be relevant 
for exposure to Giardia, as an older individual will have a greater chance of being exposed. A 
good method to determine whether an individual previously has had Giardia infection, would 
have been a good tool in order to find true low risk healthy controls.   
  Serology has can be useful to separate individuals who have had or have current 
infection with Giardia [28, 57]. Giardia IgM has shown to be increased in response to infection 
and could be useful for identifying individuals with current infection. IgG could also be useful 
to filter out Giardia exposed individuals, but cannot discriminate between past or current 
infection [28]. Low risk healthy controls should not be positive for Giardia-specific antibodies 
in order to be classified as an unexposed control.  
5.3.4 The sonicated soluble proteins from Giardia trophozoites 
The sonicated supernatant proteins from Giardia contains a mixture of many different soluble 
proteins potentially acting as antigens. As seen in an earlier study [10] we also found 
considerable cross reactivity between assemblage A and assemblage B Giardia isolates. We 
generally found lower responses to SSB compared to SSA.  One reason for this could be that 






Initial concentration of proteins were therefore higher in the SSA solution, than in the SSB 
solution. Even if we adjusted for this by measuring protein concentration and diluting to the 
same concentrations in stock solutions, this might have led to quantitative or qualitative 
differences between SSA and SSB, other than just their inherent assemblage differences. 
  Responses that could be observed in the low risk controls and in the exposed group in 
addition to cross reactivity can also have been affected by contamination of stimulatory agents 
in the growth medium. Bacterial or viral parts cannot be guaranteed to be absent even if all 
experiments were done in a sterile environment.  
  Trophozoites from clinical samples are difficult to culture [82]. The soluble proteins 
used in the present study are from trophozoites growing and replicating in culture, thus under 
unnatural conditions, and may have lost some of their virulence. Differences between 
pathogenic Giardia strains from clinical samples and Giardia strains grown in culture cannot 
be excluded. Strain differences may result in different proteins being up-regulated in the 
trophozoites and variability in virulence factors being present.  The participants exposed to 
Giardia might have stronger reactions towards other variants of the extracellular Giardia-
specific proteins on the surface known as VSPs.  
  The lack of differential responses between the exposed and unexposed group might be 
due to non-specific responses towards the large number of different proteins in the SSA and 
SSB mixtures. Identification and use of single Giardia-specific proteins or Giardia-specific 
peptides is likely to improve the specificity of the assay.  
   Proteins inhibiting cell activation and proliferation, such as ADI [23], could be present  
in the SSA and or SSB soluble protein solutions. Proliferation of PBMCs has been shown to be 
decreased if high concentrations of SSA and SSB were used in the stimulation [10], suggesting 
that proteins being able to reduce responses also can be present in the Giardia soluble proteins 
used in this study.  
5.4 statistics 
Multiple testing was done in this study between the recent giardiasis group and the low risk 
control group. Bonferroni correction can be used to adjust the level of significance when 
multiple comparisons are performed in a large dataset at the same time [83]. We did not do such 







5.5 Limitations of the study 
One limitation of the study is that a small study population was recruited. Laboratory confirmed 
Giardia infection is relatively uncommon in Norway. Individuals with recent giardiasis were 
included with a time span ranging from current, on-going, infection to over 2 years since 
successful treatment. The long time span, and the age of the participants which varied from  
22 – 69 years probably cause a large variability in response measurements. Two individuals 
with current infection were unexpectedly included, and these were not included in statistical 
analysis but their data were qualitatively compared to the responses in the two larger groups.  
  Day-to-day variations in the flow cytometer and not running compensation controls on 
the flow cytometer prior to every experience could have influenced the results. Day-to-day 
variations for FAB concentrations, temperatures and exposure to light during the staining or 
after the staining could also influence the results.  
  δγ T cells were not excluded in this study. It has been reported that 0.02-0.4% of human 
δγ T cells may recognize PE as a specific antigen [84]. Thus, these cells can contribute to non-
specific staining of the PE-fluorochrome and lead to false positive events.  
  Various cell concentrations were used in the day one assay (6 x 105 – 1 x 106) and could 
influence the number of responding antigen-specific cells per well and lead to different cytokine 
responses. 
  The statistics were not adjusted for multiple comparisons and caution should therefore 
be taken when interpreting the results.  
 
5.6 Conclusion  
In this study we show that flow cytometric assays measuring immune responses during antigen 
stimulation with soluble proteins from Giardia lamblia assemblage A and B, was possible to 
develop. The effector memory CD4+ T cell responses seen in this study did not give more 
information on Giardia-specific immunity compared to the responses seen for the general CD4+ 
T cell population when stimulated with SSA or SSB (Appendix E).  
  The increased IL-17A expression after 24 hours PBMC stimulation with SSA and SSB 
in the exposed group, especially found in individuals with current Giardia infection, could 
mean that Th17 responses are dominant. However, a larger study population of individuals with 
current giardiasis is needed to qualify the responses seen in this study.  
  The up-regulation of the surface markers CD45RO and HLA-DR seen in the exposed 






cells recognizes soluble fractions of proteins from Giardia. Up-regulation of the surface 
markers CD45RO and HLA-DR suggests that these surface markers can be used to investigate 
specific immune responses.   
  Combination of CD25 and CD26 to investigate Giardia-specific immune responses did 
not show statistical differences between the groups, and may not be a good marker of Giardia-
specific immune responses.  
  No statistically significant differences in Giardia specific T cell proliferation between 
the two groups were seen in this study. However, the small study population could be 
contributing factor to the results seen, and effector cells can exert their functions without 
specific proliferation.  
  In this study we can conclude that Th17 polarization of the T cell response may be 
important in Giardia infection and the up-regulation of surface activation markers on CD4+ 
cells suggests that cellular immunity is important in Giardia infection. The Giardia-specific 
immune responses could have been improved using purified recombinant Giardia proteins as 
antigens.   
  Cell-mediated immunity can thus be speculated to be an important factor for protection 
and perhaps eradication of giardiasis. However, a larger study population is needed to 
strengthen these findings.  
 
5.7 Further research  
Infection with Giardia is mostly associated with developing countries where it can give rise to 
dehydration due to diarrhea and contribute to malnutrition and other serious complications. 
More research investigating immune responses in humans against Giardia is important for 
instance to develop a successful vaccine. A vaccine has been developed for domestics pets such 
as cats and dogs [85] but efficacy has been questionable. A vaccine for humans would be useful 
to protect against infection, decrease Giardia resistance to antibiotics and decrease serious 
complications that can follow an infection.    
  It would have been interesting to have stimulated PBMCs with surface VSPs from 
Giardia and compare cellular responses to PBMCs stimulated with soluble intracellular Giardia 
proteins. In order to maximize chances of recognition of a VSP, either focusing on a limited 
number of semi conserved VSP regions or including all the over 200 VSPs could be used in the 
stimulation. As Giardia has capacity for antigenic variation [51], only using one or a few VSPs 






  Due to the low prevalence of Giardia infections in Norway, investigation of IL-17A, 
surface activation markers and proliferation responses in endemic areas would be fruitful. 
Individuals living in endemic areas probably have encountered the parasite several times, and 
the immune responses might be different.  Other factors, including humoral immunity, might 
be protecting individual from Giardia infection.  
  Further, it would be interesting to compare the IL-17A responses in three different 
groups of Giardia infected individuals, where one group had current giardiasis, one group had 
chronic infection and another one had asymptomatic infection, to assess differences in immune 
responses between individuals, and get a better insight into immune responses in individuals 
leading to different clinical manifestations.  
  Next, it would have been interesting to look at the local immune responses induced in 
the epithelial barrier of the small intestine during a Giardia infection. This could have been 
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Appendix C: Flow cytometric lasers, wavelengths (BP 
















































Appendix D: Exploration of CD8 cytotoxicity 
 
Table D.1: Fluorochrome-conjugated antibodies tested for investigated cytotoxicity of CD8+ cells. 
Antibody Clone Fluorochr
ome 
Isotype Concentration Supplier Catalog 
nr. 
Perforin        dG9 PE M* IgG2b, κ 100 µg/mL BioLegend 308105 
Perforin B-D48 PE M* IgG1, κ 12 µg/mL BioLegend 353303 
CD69            FN50 PE-CF594 M* IgG1, κ 50 µg/mL BD Biosciences 562617 
CD107a                       H4A3 PE-Cy™7 M* IgG1, κ 12 µg/mL BD biosciences 561348 
* = Mouse  
 
Table D.2: Protein Transport inhibitor for investigating cytotoxicity of CD8+ cells. 
Name of reagent Supplier Catalog nr 
BD GolgiStop™ Protein Transport 
inhibitor (containing Monensin) 
BD Biosciences 554724 
 
Table D.3: Alternative fluorochrome panel for day one assay looking at CD4+ and CD8+ T cell responses. 
Antigen/dye Fluorochrome Supplier 
TNF-α Brilliant™ Violet 421 Bio Legend 
IL-17A Brilliant™ Violet 605 Bio Legend 
CD8a Brilliant™ Violet 711 Bio Legend 
IFN-γ FITC BD Biosciences 
CD4 PerCP-Cy5.5 BD Biosciences 
Perforin PE Bio Legend 
CD69 PE-CF594 BD Biosciences 
IL-4 APC Bio Legend 
CD3 Alexa Fluor 700 Bio Legend 
LIVE/DEAD APC-H7 Life Technologies 








Table D.4: Alternative fluorochrome panel for day six for looking at CD4+ and CD8+ T 
cell responses 
Antigen/dye Fluorochrome Supplier 
CellTrace Pacific blue Life Technologies 
CD45RO Brilliant™ Violet 605 Bio Legend 
CD8a Brilliant™ Violet 711 Bio Legend 
HLA-DR FITC BD Biosciences 
CD4 PerCP-Cy5.5 BD Biosciences 
CD26 PE Bio Legend 
CD197 PE-CF594 BD Biosciences 
CD107a PE-Cy7 Bio Legend 
CD25 APC BD Biosciences 
CD3 Alexa Fluor 700 Bio Legend 
LIVE/DEAD APC-H7 Life Technologies 










Appendix E: SSA and SSB response data 
 
Table E.1:  Responses to SSA and SSB stimulation after one day (percentage of cytokine producing 
effector memory CD4+ T cells and CD4+ T cells), and day six (percentages of CD4+ T cells with surface 
markers and proliferating CD4+ T cells). 
 














SSA, Day one, 
Effector memory CD4 T cells 
    
  TNF-α, mean (SD) 2.01 (1.22) 0.57 (0.63) 0.30 (0.34) 0.148 
  IFN-γ, mean (SD) 0.50 (0.09) 0.19 (0.32) 0.10 (0.06) 0.773 
  TNF-α & INF-γ, mean (SD) 0.43 (0.12) 0.16 (0.25) 0.08 (0.10) 0.512 
  IL-17A, mean (SD) 1.11 (0.62) 0.14 (0.14) 0.03 (0.05) 0.035 
  IL-4, mean (SD) 0.014 (0.008) 0.009 (0.026) 0.022 (0.057) 0.210 
  IL-10, mean (SD) 0.07 (0.28) 0.01 (0.018) 0.01 (0.11) 0.938 
SSA, Day one 
CD4 T cells 
    
  TNF-α, mean (SD) 0.48 (0.18) 0.22 (0.22) 0.15 (0.19) 0.152 
  IFN-γ, mean (SD) 0.07 (0.01) 0.03 (0.07) 0.03 (0.03) 0.229 
  TNF-α & INF-γ, mean (SD) 0.057 (0.003) 0.023 (0.034) 0.016 (0.027) 0.376 
  IL-17A, mean (SD) 0.10 (0.01) 0.03 (0.03) 0.01 (0.02) 0.043 
  IL-4, mean (SD) 0.001 (0.002) 0.004 (0.011) 0.004 (0.009) 0.431 
  IL-10, mean (SD) 0.01 (0.000) 0.002 (0.004) 0.004 (0.009) 0.347 
SSA, Day six, CD4 T cells     
  CD25+CD26+, mean (SD) 3.32 (4.08) 2.24 (3.98) 0.42 (0.64) 0.088 
  HLADR+CD45RO+, mean (SD) 6.82 (5.96) 5.41 (7.16) 0.88 (1.29) 0.036 
  CD25+CD26+ and  
  HLADR+CD45RO+, mean (SD) 
1.33 (1.51) 1.41 (2.80) 0.14 (0.25) 0.042 
  Proliferation, mean (SD) 17.8 (19.9) 10.2 (11.5) 3.4 (5.0) 0.208 
SSB, Day one,  
Effector memory CD4 T cells     
  TNF-α, mean (SD) 1.18 (0.86) 0.44 (0.39) 0.26 (0.24) 0.284 
  IFN-γ, mean (SD) 0.39 (0.24) 0.97 (0.12) 0.08 (0.08) 0.914 
  TNF-α & INF-γ, mean (SD) 0.32 (0.21) 0.97 (0.12) 0.06 (0.06) 0.473 
  IL-17A, mean (SD) 0.83 (0.61) 0.12 (0.15) 0.03 (0.05) 0.062 
  IL-4, mean (SD) 0.007 (0.009) 0.014 (0.040) 0.013 (0.032) 0.889 
  IL-10, mean (SD) 0.029 (0.022) 0.011 (0.013) 0.004 (0.007) 0.082 
SSB, Day one,  
CD4 T cells 
    
  TNF-α, mean (SD) 0.22 (0.17) 0.15 (0.14) 0.10 (0.12) 0.291 
  IFN-γ, mean (SD) 0.04 (0.16) 0.28 (0.06) 0.02 (0.02) 0.328 
  TNF-α & INF-γ, mean (SD) 0.03 (0.02) 0.01 (0.02) 0.01 (0.02) 0.648 
  IL-17A, mean (SD) 0.09 (0.03) 0.03 (0.02) 0.01 (0.02) 0.037 
  IL-4, mean (SD) 0.002 (0.002) 0.006 (0.019) 0.001 (0.002) 0.167 
  IL-10, mean (SD) 0.005 (0.001) 0.003 (0.005) 0.002 (0.002) 0.463 
SSB, Day six, CD4 T cells     
  CD25+CD26+, mean (SD) 0.49 (0.23) 0.85 (1.19) 0.34 (0.43) 0.291 
  HLADR+CD45RO+, mean (SD) 3.36 (0.98) 2.53 (3.03) 0.39 (0.37) 0.057 
  CD25+CD26+ and 
  HLADR+CD45RO+, mean (SD) 
0.31 (0.12) 0.49 (0.76) 0.06 (0.07) 0.067 
  Proliferation, mean (SD) 5.11 (0.58) 3.75 (4.62) 1.07 (1.56) 0.067 
